PMCID	SUBJECT_SCOPE_ID	S_START	S_END	SUBJECT_SCOPE	CONCEPT	IGNORANCE TYPE	C_START	C_END	CONCEPT_MENTION_ID
PMC3272870	PMC3272870.nxml.gz-30893	[78]	[174]	Thyroid cancer, the most common endocrine malignancy, is often detected in young female patients	most common	IMPORTANT_CONSIDERATION	[98]	[109]	PMC3272870.nxml.gz-30891
PMC3272870	PMC3272870.nxml.gz-5	[381]	[624]	Differentiated thyroid cancer (DTC) in young people generally has an excellent prognosis, and disease-free survival among women with DTC diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	generally	PROBABLE_UNDERSTANDING	[433]	[442]	PMC3272870.nxml.gz-6
PMC3272870	PMC3272870.nxml.gz-5	[381]	[624]	Differentiated thyroid cancer (DTC) in young people generally has an excellent prognosis, and disease-free survival among women with DTC diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	may	INCOMPLETE_EVIDENCE	[545]	[548]	PMC3272870.nxml.gz-7
PMC3272870	PMC3272870.nxml.gz-5	[381]	[624]	Differentiated thyroid cancer (DTC) in young people generally has an excellent prognosis, and disease-free survival among women with DTC diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	similar	SUPERFICIAL_RELATIONSHIP	[609]	[616]	PMC3272870.nxml.gz-9
PMC3272870	PMC3272870.nxml.gz-11	[626]	[905]	However, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal and foetal management	However	ALTERNATIVE_OPTIONS_CONTROVERSY	[626]	[633]	PMC3272870.nxml.gz-10
PMC3272870	PMC3272870.nxml.gz-11	[626]	[905]	However, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal and foetal management	may	INCOMPLETE_EVIDENCE	[676]	[679]	PMC3272870.nxml.gz-12
PMC3272870	PMC3272870.nxml.gz-11	[626]	[905]	However, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal and foetal management	obviously	IMPORTANT_CONSIDERATION	[854]	[863]	PMC3272870.nxml.gz-15
PMC3272870	PMC3272870.nxml.gz-11	[626]	[905]	However, thyroid cancer detected during pregnancy may cause anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity, as weel as pregnancy following a diagnosis of thyroid cancer obviously needs both maternal and foetal management	needs	IMPORTANT_CONSIDERATION	[864]	[869]	PMC3272870.nxml.gz-16
PMC3272870	PMC3272870.nxml.gz-18	[907]	[1348]	The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for the mother and to plan further therapy when needed	objectives	IMPORTANT_CONSIDERATION	[916]	[926]	PMC3272870.nxml.gz-19
PMC3272870	PMC3272870.nxml.gz-18	[907]	[1348]	The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for the mother and to plan further therapy when needed	required	IMPORTANT_CONSIDERATION	[1083]	[1091]	PMC3272870.nxml.gz-20
PMC3272870	PMC3272870.nxml.gz-18	[907]	[1348]	The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for the mother and to plan further therapy when needed	possible	INCOMPLETE_EVIDENCE	[1212]	[1220]	PMC3272870.nxml.gz-21
PMC3272870	PMC3272870.nxml.gz-18	[907]	[1348]	The main objectives in clinical monitoring of pregnant thyroid cancer patients are: 1) to reach an adequate balance of maternal calcium and thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation; 2) to maintain optimal levels of maternal thyroxin to avoid possible recurrence or spread of disease; and 3) to perform safe follow-up visits for the mother and to plan further therapy when needed	safe	IMPORTANT_CONSIDERATION	[1272]	[1276]	PMC3272870.nxml.gz-22
PMC3272870	PMC3272870.nxml.gz-23	[1350]	[1666]	Data from a review of the literature and the authors' own experience show that in patients undergoing either suppressive or substitutive thyroxine therapy foetal thyroid growth is normal at ultrasound study, newborn thyroid status is normal, and the incidence of maternal morbidity is not influenced by the pregnancy	review of the literature	INCOMPLETE_EVIDENCE	[1362]	[1386]	PMC3272870.nxml.gz-24
PMC3272870	PMC3272870.nxml.gz-23	[1350]	[1666]	Data from a review of the literature and the authors' own experience show that in patients undergoing either suppressive or substitutive thyroxine therapy foetal thyroid growth is normal at ultrasound study, newborn thyroid status is normal, and the incidence of maternal morbidity is not influenced by the pregnancy	own experience	INCOMPLETE_EVIDENCE	[1404]	[1418]	PMC3272870.nxml.gz-25
PMC3272870	PMC3272870.nxml.gz-23	[1350]	[1666]	Data from a review of the literature and the authors' own experience show that in patients undergoing either suppressive or substitutive thyroxine therapy foetal thyroid growth is normal at ultrasound study, newborn thyroid status is normal, and the incidence of maternal morbidity is not influenced by the pregnancy	show	INCOMPLETE_EVIDENCE	[1419]	[1423]	PMC3272870.nxml.gz-26
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	this review	QUESTION_ANSWERED_BY_THIS_WORK	[1671]	[1682]	PMC3272870.nxml.gz-30
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	underline	PROBABLE_UNDERSTANDING	[1696]	[1705]	PMC3272870.nxml.gz-31
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	outmost importance	IMPORTANT_CONSIDERATION	[1774]	[1792]	PMC3272870.nxml.gz-32
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	some	INCOMPLETE_EVIDENCE	[1843]	[1847]	PMC3272870.nxml.gz-33
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	insight	INCOMPLETE_EVIDENCE	[1848]	[1855]	PMC3272870.nxml.gz-34
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	interesting	ANOMALY_CURIOUS_FINDING	[1862]	[1873]	PMC3272870.nxml.gz-35
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	point of view	INCOMPLETE_EVIDENCE	[1891]	[1904]	PMC3272870.nxml.gz-36
PMC3272870	PMC3272870.nxml.gz-29	[1668]	[2001]	In this review, the authors underline that regular adjustment of levo-thyroxine and calcium therapy is of outmost importance for both maternal and foetal well-being and offer some insight, very interesting from a practical point of view, to provide a clear and simple pathway for the management of pregnancy-associated thyroid cancer	associated	SUPERFICIAL_RELATIONSHIP	[1976]	[1986]	PMC3272870.nxml.gz-37
PMC3272870	PMC3272870.nxml.gz-40	[2222]	[2343]	For these reasons, differentiated thyroid cancer (DTC) is one of the most common cancers in women in the reproductive age	reasons	PROBABLE_UNDERSTANDING	[2232]	[2239]	PMC3272870.nxml.gz-42
PMC3272870	PMC3272870.nxml.gz-40	[2222]	[2343]	For these reasons, differentiated thyroid cancer (DTC) is one of the most common cancers in women in the reproductive age	most common	IMPORTANT_CONSIDERATION	[2291]	[2302]	PMC3272870.nxml.gz-43
PMC3272870	PMC3272870.nxml.gz-45	[2345]	[2504]	Hence, thyroid cancer ranks among the most common cancers during pregnancy, with a prevalence of 3.6-14 per 100,000 live births, mirroring the its incidence1-4	Hence	PROBABLE_UNDERSTANDING	[2345]	[2350]	PMC3272870.nxml.gz-44
PMC3272870	PMC3272870.nxml.gz-45	[2345]	[2504]	Hence, thyroid cancer ranks among the most common cancers during pregnancy, with a prevalence of 3.6-14 per 100,000 live births, mirroring the its incidence1-4	most common	IMPORTANT_CONSIDERATION	[2383]	[2394]	PMC3272870.nxml.gz-46
PMC3272870	PMC3272870.nxml.gz-50	[2706]	[2838]	Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours	Some	INCOMPLETE_EVIDENCE	[2706]	[2710]	PMC3272870.nxml.gz-49
PMC3272870	PMC3272870.nxml.gz-50	[2706]	[2838]	Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours	suggest	INCOMPLETE_EVIDENCE	[2716]	[2723]	PMC3272870.nxml.gz-51
PMC3272870	PMC3272870.nxml.gz-50	[2706]	[2838]	Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours	importance	IMPORTANT_CONSIDERATION	[2728]	[2738]	PMC3272870.nxml.gz-52
PMC3272870	PMC3272870.nxml.gz-50	[2706]	[2838]	Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours	mainly	PROBABLE_UNDERSTANDING	[2758]	[2764]	PMC3272870.nxml.gz-53
PMC3272870	PMC3272870.nxml.gz-50	[2706]	[2838]	Some data suggest the importance of growth factors (mainly TSH, but also HCG) in growth, progression and spread of papillary tumours	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[2770]	[2773]	PMC3272870.nxml.gz-54
PMC3272870	PMC3272870.nxml.gz-55	[2840]	[3112]	In vitro oestrogens have been shown to down-regulate the NIS (sodium iodide symporter) gene and promote the production of thyroglobulin (HTG), increasing HTG-gene expression via oestrogen receptors present in thyroid tissue, without stimulating rapid cell proliferation145	have been shown	INCOMPLETE_EVIDENCE	[2860]	[2875]	PMC3272870.nxml.gz-56
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	could	INCOMPLETE_EVIDENCE	[3119]	[3124]	PMC3272870.nxml.gz-58
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	support	INCOMPLETE_EVIDENCE	[3125]	[3132]	PMC3272870.nxml.gz-59
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	hypothesis	INCOMPLETE_EVIDENCE	[3137]	[3147]	PMC3272870.nxml.gz-60
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	therefore	PROBABLE_UNDERSTANDING	[3171]	[3180]	PMC3272870.nxml.gz-61
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	may	INCOMPLETE_EVIDENCE	[3217]	[3220]	PMC3272870.nxml.gz-62
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	although	ANOMALY_CURIOUS_FINDING	[3259]	[3267]	PMC3272870.nxml.gz-63
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	associations	SUPERFICIAL_RELATIONSHIP	[3274]	[3286]	PMC3272870.nxml.gz-64
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	could	INCOMPLETE_EVIDENCE	[3295]	[3300]	PMC3272870.nxml.gz-66
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	indicate	INCOMPLETE_EVIDENCE	[3301]	[3309]	PMC3272870.nxml.gz-67
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	either ... or	ALTERNATIVE_OPTIONS_CONTROVERSY	[3310, 3331]	[3316, 3333]	PMC3272870.nxml.gz-68
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	link	SUPERFICIAL_RELATIONSHIP	[3326]	[3330]	PMC3272870.nxml.gz-70
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	bias	PROBLEM_COMPLICATION	[3349]	[3353]	PMC3272870.nxml.gz-71
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	may	INCOMPLETE_EVIDENCE	[3356]	[3359]	PMC3272870.nxml.gz-73
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	reflect	SUPERFICIAL_RELATIONSHIP	[3360]	[3367]	PMC3272870.nxml.gz-74
PMC3272870	PMC3272870.nxml.gz-57	[3114]	[3445]	This could support the hypothesis that sex hormones and, therefore, menstrual and reproductive events, may modify thyroid cancer risk in women6, although these associations – which could indicate either a causal link or a surveillance bias – may reflect an aetiology shared by both the above-mentioned factors and by thyroid cancer	factors	SUPERFICIAL_RELATIONSHIP	[3416]	[3423]	PMC3272870.nxml.gz-75
PMC3272870	PMC3272870.nxml.gz-77	[3447]	[3498]	However, such a relation has not yet been confirmed	However	ALTERNATIVE_OPTIONS_CONTROVERSY	[3447]	[3454]	PMC3272870.nxml.gz-76
PMC3272870	PMC3272870.nxml.gz-77	[3447]	[3498]	However, such a relation has not yet been confirmed	relation	SUPERFICIAL_RELATIONSHIP	[3463]	[3471]	PMC3272870.nxml.gz-78
PMC3272870	PMC3272870.nxml.gz-77	[3447]	[3498]	However, such a relation has not yet been confirmed	not yet	FULL_UNKNOWN	[3476]	[3483]	PMC3272870.nxml.gz-79
PMC3272870	PMC3272870.nxml.gz-81	[3500]	[3665]	The diagnosis of a tumour during pregnancy obviously causes anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity	obviously	IMPORTANT_CONSIDERATION	[3543]	[3552]	PMC3272870.nxml.gz-83
PMC3272870	PMC3272870.nxml.gz-81	[3500]	[3665]	The diagnosis of a tumour during pregnancy obviously causes anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity	optimal	IMPORTANT_CONSIDERATION	[3578]	[3585]	PMC3272870.nxml.gz-85
PMC3272870	PMC3272870.nxml.gz-81	[3500]	[3665]	The diagnosis of a tumour during pregnancy obviously causes anxiety about the optimal timing of recommended treatments and about both maternal and neonatal morbidity	recommended	FUTURE_WORK	[3596]	[3607]	PMC3272870.nxml.gz-86
PMC3272870	PMC3272870.nxml.gz-88	[3667]	[3896]	However, thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	However	ALTERNATIVE_OPTIONS_CONTROVERSY	[3667]	[3674]	PMC3272870.nxml.gz-87
PMC3272870	PMC3272870.nxml.gz-88	[3667]	[3896]	However, thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	generally	PROBABLE_UNDERSTANDING	[3711]	[3720]	PMC3272870.nxml.gz-89
PMC3272870	PMC3272870.nxml.gz-88	[3667]	[3896]	However, thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	may	INCOMPLETE_EVIDENCE	[3817]	[3820]	PMC3272870.nxml.gz-90
PMC3272870	PMC3272870.nxml.gz-88	[3667]	[3896]	However, thyroid cancer in young people has generally an excellent prognosis, and survival among women with thyroid cancer diagnosed during pregnancy may not differ from that in age-matched non-pregnant women with similar disease	similar	SUPERFICIAL_RELATIONSHIP	[3881]	[3888]	PMC3272870.nxml.gz-92
PMC3272870	PMC3272870.nxml.gz-93	[3898]	[4017]	Pregnancy is a special situation in oncology: we need to control two patients at the same time, and both are vulnerable	special	ANOMALY_CURIOUS_FINDING	[3913]	[3920]	PMC3272870.nxml.gz-94
PMC3272870	PMC3272870.nxml.gz-93	[3898]	[4017]	Pregnancy is a special situation in oncology: we need to control two patients at the same time, and both are vulnerable	need	IMPORTANT_CONSIDERATION	[3947]	[3951]	PMC3272870.nxml.gz-95
PMC3272870	PMC3272870.nxml.gz-96	[4019]	[4130]	In addition, each situation must be considered in development, nothing is static, mainly in the first trimester	must be	IMPORTANT_CONSIDERATION	[4047]	[4054]	PMC3272870.nxml.gz-97
PMC3272870	PMC3272870.nxml.gz-96	[4019]	[4130]	In addition, each situation must be considered in development, nothing is static, mainly in the first trimester	considered	IMPORTANT_CONSIDERATION	[4055]	[4065]	PMC3272870.nxml.gz-98
PMC3272870	PMC3272870.nxml.gz-96	[4019]	[4130]	In addition, each situation must be considered in development, nothing is static, mainly in the first trimester	mainly	PROBABLE_UNDERSTANDING	[4101]	[4107]	PMC3272870.nxml.gz-100
PMC3272870	PMC3272870.nxml.gz-101	[4132]	[4267]	Finally, thyroid cancer patients often undergo total thyroidectomy and thus need adequate supplementation of both calcium and thyroxine	often	PROBABLE_UNDERSTANDING	[4165]	[4170]	PMC3272870.nxml.gz-102
PMC3272870	PMC3272870.nxml.gz-101	[4132]	[4267]	Finally, thyroid cancer patients often undergo total thyroidectomy and thus need adequate supplementation of both calcium and thyroxine	thus	PROBABLE_UNDERSTANDING	[4203]	[4207]	PMC3272870.nxml.gz-103
PMC3272870	PMC3272870.nxml.gz-101	[4132]	[4267]	Finally, thyroid cancer patients often undergo total thyroidectomy and thus need adequate supplementation of both calcium and thyroxine	need	IMPORTANT_CONSIDERATION	[4208]	[4212]	PMC3272870.nxml.gz-104
PMC3272870	PMC3272870.nxml.gz-106	[4269]	[4348]	Thus, pregnancy following thyroid cancer needs both maternal and foetal control	Thus	PROBABLE_UNDERSTANDING	[4269]	[4273]	PMC3272870.nxml.gz-105
PMC3272870	PMC3272870.nxml.gz-106	[4269]	[4348]	Thus, pregnancy following thyroid cancer needs both maternal and foetal control	needs	IMPORTANT_CONSIDERATION	[4310]	[4315]	PMC3272870.nxml.gz-107
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	problems	PROBLEM_COMPLICATION	[4359]	[4367]	PMC3272870.nxml.gz-109
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	required	IMPORTANT_CONSIDERATION	[4453]	[4461]	PMC3272870.nxml.gz-110
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	possible	INCOMPLETE_EVIDENCE	[4578]	[4586]	PMC3272870.nxml.gz-111
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	safe	IMPORTANT_CONSIDERATION	[4640]	[4644]	PMC3272870.nxml.gz-112
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	to plan	FUTURE_WORK	[4683]	[4690]	PMC3272870.nxml.gz-113
PMC3272870	PMC3272870.nxml.gz-108	[4350]	[4718]	The main problems are: i) to reach an adequate balance of maternal thyroid hormones that is absolutely required by the foetal central nervous system for normal maturation7, ii) to maintain maternal levels of l-thyroxin to avoid possible recurrence or spread of disease, and iii) to perform safe follow-up controls for the mother and to plan further therapy when needed	needed	FUTURE_WORK	[4712]	[4718]	PMC3272870.nxml.gz-114
PMC3272870	PMC3272870.nxml.gz-115	[5029]	[5302]	Thyroid hormones are major factors for the normal development of foetal brain, and until the end of the first trimester, when the hypothalamic-pituitary- thyroid axis becomes functional, the foetal brain is strictly dependent on local deiodination of maternal thyroxine7-12	major	IMPORTANT_CONSIDERATION	[5050]	[5055]	PMC3272870.nxml.gz-116
PMC3272870	PMC3272870.nxml.gz-115	[5029]	[5302]	Thyroid hormones are major factors for the normal development of foetal brain, and until the end of the first trimester, when the hypothalamic-pituitary- thyroid axis becomes functional, the foetal brain is strictly dependent on local deiodination of maternal thyroxine7-12	factors	SUPERFICIAL_RELATIONSHIP	[5056]	[5063]	PMC3272870.nxml.gz-117
PMC3272870	PMC3272870.nxml.gz-118	[5304]	[5512]	Thyroid hormone deficiency may cause severe neurologic disorders, resulting from defects in neuronal cell differentiation and migration, axonal and dendritic outgrowth, myelin formation and synaptogenesis7913	may	INCOMPLETE_EVIDENCE	[5331]	[5334]	PMC3272870.nxml.gz-119
PMC3272870	PMC3272870.nxml.gz-118	[5304]	[5512]	Thyroid hormone deficiency may cause severe neurologic disorders, resulting from defects in neuronal cell differentiation and migration, axonal and dendritic outgrowth, myelin formation and synaptogenesis7913	severe	IMPORTANT_CONSIDERATION	[5341]	[5347]	PMC3272870.nxml.gz-120
PMC3272870	PMC3272870.nxml.gz-121	[5514]	[5701]	The offspring of women with a serum-free thyroxine (fT4) concentration in the lowest decile of the reference range at 12 weeks of gestation may have significant delays in neurodevelopment	may	INCOMPLETE_EVIDENCE	[5654]	[5657]	PMC3272870.nxml.gz-122
PMC3272870	PMC3272870.nxml.gz-125	[5865]	[6055]	During pregnancy, the mother's thyroid physiology undergoes many well-defined changes, leading to an increase in thyroid volume which is often associated with higher urinary iodine excretion	well-defined	INCOMPLETE_EVIDENCE	[5930]	[5942]	PMC3272870.nxml.gz-126
PMC3272870	PMC3272870.nxml.gz-125	[5865]	[6055]	During pregnancy, the mother's thyroid physiology undergoes many well-defined changes, leading to an increase in thyroid volume which is often associated with higher urinary iodine excretion	often	PROBABLE_UNDERSTANDING	[6002]	[6007]	PMC3272870.nxml.gz-127
PMC3272870	PMC3272870.nxml.gz-125	[5865]	[6055]	During pregnancy, the mother's thyroid physiology undergoes many well-defined changes, leading to an increase in thyroid volume which is often associated with higher urinary iodine excretion	associated	SUPERFICIAL_RELATIONSHIP	[6008]	[6018]	PMC3272870.nxml.gz-128
PMC3272870	PMC3272870.nxml.gz-129	[6057]	[6174]	It is also associated with the formation of new thyroid nodules with the histological features of nodular hyperplasia	associated	SUPERFICIAL_RELATIONSHIP	[6068]	[6078]	PMC3272870.nxml.gz-130
PMC3272870	PMC3272870.nxml.gz-131	[6176]	[6394]	Very early in pregnancy, the increase in oestrogen levels causes an approximate doubling in thyroxine-binding globulin (TBG) that can lead to an increases in total T4 concentration and a reduced free fraction (Table I)	approximate	INCOMPLETE_EVIDENCE	[6244]	[6255]	PMC3272870.nxml.gz-132
PMC3272870	PMC3272870.nxml.gz-131	[6176]	[6394]	Very early in pregnancy, the increase in oestrogen levels causes an approximate doubling in thyroxine-binding globulin (TBG) that can lead to an increases in total T4 concentration and a reduced free fraction (Table I)	can	INCOMPLETE_EVIDENCE	[6306]	[6309]	PMC3272870.nxml.gz-133
PMC3272870	PMC3272870.nxml.gz-131	[6176]	[6394]	Very early in pregnancy, the increase in oestrogen levels causes an approximate doubling in thyroxine-binding globulin (TBG) that can lead to an increases in total T4 concentration and a reduced free fraction (Table I)	lead to	SUPERFICIAL_RELATIONSHIP	[6310]	[6317]	PMC3272870.nxml.gz-134
PMC3272870	PMC3272870.nxml.gz-135	[6396]	[6529]	In healthy women, the final effect consists of a significant increase in the total thyroxine pool, mainly in the first trimester17-19	effect	SUPERFICIAL_RELATIONSHIP	[6424]	[6430]	PMC3272870.nxml.gz-136
PMC3272870	PMC3272870.nxml.gz-135	[6396]	[6529]	In healthy women, the final effect consists of a significant increase in the total thyroxine pool, mainly in the first trimester17-19	mainly	PROBABLE_UNDERSTANDING	[6495]	[6501]	PMC3272870.nxml.gz-137
PMC3272870	PMC3272870.nxml.gz-138	[6531]	[6698]	This increment may be brought about largely by thyroid stimulation induced by human chorionic gonadotropin (HCG) through its structural affinity with thyrotropin (TSH)	may be	INCOMPLETE_EVIDENCE	[6546]	[6552]	PMC3272870.nxml.gz-139
PMC3272870	PMC3272870.nxml.gz-138	[6531]	[6698]	This increment may be brought about largely by thyroid stimulation induced by human chorionic gonadotropin (HCG) through its structural affinity with thyrotropin (TSH)	largely	INCOMPLETE_EVIDENCE	[6567]	[6574]	PMC3272870.nxml.gz-140
PMC3272870	PMC3272870.nxml.gz-141	[6700]	[6897]	It can be observed that a slight increase in fT4 and a reduction in TSH occur between the 9thand 12thweeks of gestation; subsequently, HCG levels decrease and TSH reaches normal non-pregnant levels	observed	INCOMPLETE_EVIDENCE	[6710]	[6718]	PMC3272870.nxml.gz-143
PMC3272870	PMC3272870.nxml.gz-144	[6899]	[6995]	The TSH concentration generally lies within the normal range after the 16th to 18th week11171920	generally	PROBABLE_UNDERSTANDING	[6921]	[6930]	PMC3272870.nxml.gz-145
PMC3272870	PMC3272870.nxml.gz-146	[6997]	[7097]	In hypothyroid or thyroidectomized pregnant women, such physiological changes obviously cannot occur	obviously	ALTERNATIVE_OPTIONS_CONTROVERSY	[7075]	[7084]	PMC3272870.nxml.gz-147
PMC3272870	PMC3272870.nxml.gz-149	[7099]	[7358]	Both during suppressive or substitutive therapy, L-T4 requirement increases very early during pregnancy, reaching a plateau after 16thto 20thweeks of gestation, with a required L-T4 dosage approximately 30 to 50% higher than that administered before pregnancy	required	IMPORTANT_CONSIDERATION	[7267]	[7275]	PMC3272870.nxml.gz-150
PMC3272870	PMC3272870.nxml.gz-149	[7099]	[7358]	Both during suppressive or substitutive therapy, L-T4 requirement increases very early during pregnancy, reaching a plateau after 16thto 20thweeks of gestation, with a required L-T4 dosage approximately 30 to 50% higher than that administered before pregnancy	approximately	INCOMPLETE_EVIDENCE	[7288]	[7301]	PMC3272870.nxml.gz-151
PMC3272870	PMC3272870.nxml.gz-152	[7620]	[8038]	Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity91315-172122	well-known	PROBABLE_UNDERSTANDING	[7632]	[7642]	PMC3272870.nxml.gz-153
PMC3272870	PMC3272870.nxml.gz-152	[7620]	[8038]	Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity91315-172122	association	SUPERFICIAL_RELATIONSHIP	[7643]	[7654]	PMC3272870.nxml.gz-154
PMC3272870	PMC3272870.nxml.gz-152	[7620]	[8038]	Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity91315-172122	impaired	IMPORTANT_CONSIDERATION	[7694]	[7702]	PMC3272870.nxml.gz-155
PMC3272870	PMC3272870.nxml.gz-152	[7620]	[8038]	Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity91315-172122	inadequately	PROBLEM_COMPLICATION	[7769]	[7781]	PMC3272870.nxml.gz-156
PMC3272870	PMC3272870.nxml.gz-152	[7620]	[8038]	Besides the well-known association between gestational hypothyroidism and impaired intellectual and cognitive development in offspring, untreated or inadequately treated and subclinical hypothyroidism is associated with foetal loss, anaemia, gestational hypertension and preeclampsia, abruption placentae, increased risk of miscarriage, foetal growth retardation, perinatal mortality and neonatal morbidity91315-172122	associated	SUPERFICIAL_RELATIONSHIP	[7824]	[7834]	PMC3272870.nxml.gz-157
PMC3272870	PMC3272870.nxml.gz-158	[8040]	[8133]	Finally, for thyroid cancer patients, hypothyroidism can rise the maternal risk of recurrence	can	INCOMPLETE_EVIDENCE	[8093]	[8096]	PMC3272870.nxml.gz-159
PMC3272870	PMC3272870.nxml.gz-161	[8135]	[8320]	Thus, hypothyroidism must be absolutely avoided in all pregnant woman, especially in thyroid cancer patients, and therefore correct supplementation of thyroxine is of extreme importance	Thus	PROBABLE_UNDERSTANDING	[8135]	[8139]	PMC3272870.nxml.gz-160
PMC3272870	PMC3272870.nxml.gz-161	[8135]	[8320]	Thus, hypothyroidism must be absolutely avoided in all pregnant woman, especially in thyroid cancer patients, and therefore correct supplementation of thyroxine is of extreme importance	must be	IMPORTANT_CONSIDERATION	[8156]	[8163]	PMC3272870.nxml.gz-162
PMC3272870	PMC3272870.nxml.gz-161	[8135]	[8320]	Thus, hypothyroidism must be absolutely avoided in all pregnant woman, especially in thyroid cancer patients, and therefore correct supplementation of thyroxine is of extreme importance	therefore	PROBABLE_UNDERSTANDING	[8249]	[8258]	PMC3272870.nxml.gz-163
PMC3272870	PMC3272870.nxml.gz-161	[8135]	[8320]	Thus, hypothyroidism must be absolutely avoided in all pregnant woman, especially in thyroid cancer patients, and therefore correct supplementation of thyroxine is of extreme importance	extreme importance	IMPORTANT_CONSIDERATION	[8302]	[8320]	PMC3272870.nxml.gz-164
PMC3272870	PMC3272870.nxml.gz-166	[8362]	[8548]	Thyroidectomised patients often need calcium and D vitamin supplementation, and the treatment needs frequent adjustment during the pregnancy to prevent maternal and neonatal hypocalcemia	often	PROBABLE_UNDERSTANDING	[8388]	[8393]	PMC3272870.nxml.gz-167
PMC3272870	PMC3272870.nxml.gz-166	[8362]	[8548]	Thyroidectomised patients often need calcium and D vitamin supplementation, and the treatment needs frequent adjustment during the pregnancy to prevent maternal and neonatal hypocalcemia	need	IMPORTANT_CONSIDERATION	[8394]	[8398]	PMC3272870.nxml.gz-168
PMC3272870	PMC3272870.nxml.gz-166	[8362]	[8548]	Thyroidectomised patients often need calcium and D vitamin supplementation, and the treatment needs frequent adjustment during the pregnancy to prevent maternal and neonatal hypocalcemia	needs	IMPORTANT_CONSIDERATION	[8456]	[8461]	PMC3272870.nxml.gz-169
PMC3272870	PMC3272870.nxml.gz-170	[8550]	[8722]	During pregnancy vitamin D and calcium metabolism undergo significant changes to provide the calcium needed for maternal skeletal preservation and foetal skeletal formation	needed	IMPORTANT_CONSIDERATION	[8651]	[8657]	PMC3272870.nxml.gz-171
PMC3272870	PMC3272870.nxml.gz-172	[8724]	[8962]	Increased intestinal calcium absorption seems to be the primary mechanism for obtaining extra calcium in physiological pregnancy, but frequent nausea and vomiting or sometimes diarrhea reduce the amount of calcium absorbed by the mother23	seems	ANOMALY_CURIOUS_FINDING	[8764]	[8769]	PMC3272870.nxml.gz-173
PMC3272870	PMC3272870.nxml.gz-172	[8724]	[8962]	Increased intestinal calcium absorption seems to be the primary mechanism for obtaining extra calcium in physiological pregnancy, but frequent nausea and vomiting or sometimes diarrhea reduce the amount of calcium absorbed by the mother23	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[8854]	[8857]	PMC3272870.nxml.gz-174
PMC3272870	PMC3272870.nxml.gz-172	[8724]	[8962]	Increased intestinal calcium absorption seems to be the primary mechanism for obtaining extra calcium in physiological pregnancy, but frequent nausea and vomiting or sometimes diarrhea reduce the amount of calcium absorbed by the mother23	sometimes	INCOMPLETE_EVIDENCE	[8890]	[8899]	PMC3272870.nxml.gz-175
PMC3272870	PMC3272870.nxml.gz-30895	[9009]	[9105]	Moreover, the usual recommendations to avoid sun exposure reduces dermal synthesis of vitamin D3	recommendations	FUTURE_WORK	[9029]	[9044]	PMC3272870.nxml.gz-177
PMC3272870	PMC3272870.nxml.gz-30897	[9105]	[9250]	Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention	Although	ANOMALY_CURIOUS_FINDING	[9105]	[9113]	PMC3272870.nxml.gz-178
PMC3272870	PMC3272870.nxml.gz-30897	[9105]	[9250]	Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention	undoubtedly	PROBABLE_UNDERSTANDING	[9127]	[9138]	PMC3272870.nxml.gz-179
PMC3272870	PMC3272870.nxml.gz-30897	[9105]	[9250]	Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention	important	IMPORTANT_CONSIDERATION	[9139]	[9148]	PMC3272870.nxml.gz-180
PMC3272870	PMC3272870.nxml.gz-30897	[9105]	[9250]	Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention	know	INCOMPLETE_EVIDENCE	[9181]	[9185]	PMC3272870.nxml.gz-181
PMC3272870	PMC3272870.nxml.gz-30897	[9105]	[9250]	Although vitamin D is undoubtedly important for foetal bone development, we know that it plays a much wider role in health and disease prevention	role	SUPERFICIAL_RELATIONSHIP	[9213]	[9217]	PMC3272870.nxml.gz-182
PMC3272870	PMC3272870.nxml.gz-184	[9252]	[9356]	Not really a vitamin, D3is a pro-prehormone made in the skin in response to ultraviolet-B light exposure	Not really	ALTERNATIVE_OPTIONS_CONTROVERSY	[9252]	[9262]	PMC3272870.nxml.gz-183
PMC3272870	PMC3272870.nxml.gz-187	[9551]	[9782]	1,25(OH)2D may interfere with many functions beyond calcium metabolism, such as foetal "imprinting" that may affect neurodevelopment, immune function and chronic disease susceptibility later in life, as well as soon after birth2425	may	INCOMPLETE_EVIDENCE	[9562]	[9565]	PMC3272870.nxml.gz-188
PMC3272870	PMC3272870.nxml.gz-187	[9551]	[9782]	1,25(OH)2D may interfere with many functions beyond calcium metabolism, such as foetal "imprinting" that may affect neurodevelopment, immune function and chronic disease susceptibility later in life, as well as soon after birth2425	may	INCOMPLETE_EVIDENCE	[9656]	[9659]	PMC3272870.nxml.gz-189
PMC3272870	PMC3272870.nxml.gz-187	[9551]	[9782]	1,25(OH)2D may interfere with many functions beyond calcium metabolism, such as foetal "imprinting" that may affect neurodevelopment, immune function and chronic disease susceptibility later in life, as well as soon after birth2425	affect	SUPERFICIAL_RELATIONSHIP	[9660]	[9666]	PMC3272870.nxml.gz-190
PMC3272870	PMC3272870.nxml.gz-191	[10010]	[10161]	Vitamin D and calcium deficiency can lead to maternal anorexia with poor weight gain, and impaired bone ossification or osteopenia among newborn infant	can	INCOMPLETE_EVIDENCE	[10043]	[10046]	PMC3272870.nxml.gz-192
PMC3272870	PMC3272870.nxml.gz-191	[10010]	[10161]	Vitamin D and calcium deficiency can lead to maternal anorexia with poor weight gain, and impaired bone ossification or osteopenia among newborn infant	lead to	SUPERFICIAL_RELATIONSHIP	[10047]	[10054]	PMC3272870.nxml.gz-193
PMC3272870	PMC3272870.nxml.gz-196	[10164]	[10246]	Neonatal hypocalcemia with seizures is not uncommon in D-vitamin deficient mothers	not uncommon	INCOMPLETE_EVIDENCE	[10203]	[10215]	PMC3272870.nxml.gz-197
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	likely	PROBABLE_UNDERSTANDING	[10261]	[10267]	PMC3272870.nxml.gz-199
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	safe	IMPORTANT_CONSIDERATION	[10268]	[10272]	PMC3272870.nxml.gz-200
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	recommended	FUTURE_WORK	[10332]	[10343]	PMC3272870.nxml.gz-201
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[10424]	[10427]	PMC3272870.nxml.gz-202
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	sometimes	INCOMPLETE_EVIDENCE	[10428]	[10437]	PMC3272870.nxml.gz-203
PMC3272870	PMC3272870.nxml.gz-198	[10248]	[10470]	Vitamin D is likely safe during pregnancy and breast feeding when taken by mouth in recommended amounts, that is 10 mcg (400 USP units) of vitamin D daily in normal pregnancy. but sometimes thyroidectomised women need more	need	IMPORTANT_CONSIDERATION	[10461]	[10465]	PMC3272870.nxml.gz-204
PMC3272870	PMC3272870.nxml.gz-205	[10472]	[10694]	Dosage in excess of 50 mcg (2000 units) per day are not recommended, thus the treatment of postsurgical hypoparatithyroid patient calcium supplementation may be required at dosage as high as 4 g/day together with D vitamin	recommended	FUTURE_WORK	[10528]	[10539]	PMC3272870.nxml.gz-206
PMC3272870	PMC3272870.nxml.gz-205	[10472]	[10694]	Dosage in excess of 50 mcg (2000 units) per day are not recommended, thus the treatment of postsurgical hypoparatithyroid patient calcium supplementation may be required at dosage as high as 4 g/day together with D vitamin	thus	PROBABLE_UNDERSTANDING	[10541]	[10545]	PMC3272870.nxml.gz-207
PMC3272870	PMC3272870.nxml.gz-205	[10472]	[10694]	Dosage in excess of 50 mcg (2000 units) per day are not recommended, thus the treatment of postsurgical hypoparatithyroid patient calcium supplementation may be required at dosage as high as 4 g/day together with D vitamin	may be	INCOMPLETE_EVIDENCE	[10626]	[10632]	PMC3272870.nxml.gz-208
PMC3272870	PMC3272870.nxml.gz-205	[10472]	[10694]	Dosage in excess of 50 mcg (2000 units) per day are not recommended, thus the treatment of postsurgical hypoparatithyroid patient calcium supplementation may be required at dosage as high as 4 g/day together with D vitamin	required	IMPORTANT_CONSIDERATION	[10633]	[10641]	PMC3272870.nxml.gz-209
PMC3272870	PMC3272870.nxml.gz-210	[10696]	[10813]	The range between therapeutic and toxic doses is narrow, and vitamin D toxicity, when it occurs, is a serious problem	serious	IMPORTANT_CONSIDERATION	[10798]	[10805]	PMC3272870.nxml.gz-211
PMC3272870	PMC3272870.nxml.gz-210	[10696]	[10813]	The range between therapeutic and toxic doses is narrow, and vitamin D toxicity, when it occurs, is a serious problem	problem	IMPORTANT_CONSIDERATION	[10806]	[10813]	PMC3272870.nxml.gz-213
PMC3272870	PMC3272870.nxml.gz-214	[10815]	[10920]	The first sign is a rise in the ratio of calcium to creatinine in the urine, which precedes hypercalcemia	sign	INCOMPLETE_EVIDENCE	[10825]	[10829]	PMC3272870.nxml.gz-215
PMC3272870	PMC3272870.nxml.gz-216	[10922]	[11067]	Hypervitaminosis D is thought to be associated with a rare infant disease with supravalvular aortic stenosis, elfin facies and mental retardation	is thought	INCOMPLETE_EVIDENCE	[10941]	[10951]	PMC3272870.nxml.gz-217
PMC3272870	PMC3272870.nxml.gz-216	[10922]	[11067]	Hypervitaminosis D is thought to be associated with a rare infant disease with supravalvular aortic stenosis, elfin facies and mental retardation	thought to	INCOMPLETE_EVIDENCE	[10944]	[10954]	PMC3272870.nxml.gz-218
PMC3272870	PMC3272870.nxml.gz-216	[10922]	[11067]	Hypervitaminosis D is thought to be associated with a rare infant disease with supravalvular aortic stenosis, elfin facies and mental retardation	associated	SUPERFICIAL_RELATIONSHIP	[10958]	[10968]	PMC3272870.nxml.gz-219
PMC3272870	PMC3272870.nxml.gz-216	[10922]	[11067]	Hypervitaminosis D is thought to be associated with a rare infant disease with supravalvular aortic stenosis, elfin facies and mental retardation	rare	INCOMPLETE_EVIDENCE	[10976]	[10980]	PMC3272870.nxml.gz-220
PMC3272870	PMC3272870.nxml.gz-222	[11069]	[11241]	Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients	Thus	PROBABLE_UNDERSTANDING	[11069]	[11073]	PMC3272870.nxml.gz-221
PMC3272870	PMC3272870.nxml.gz-222	[11069]	[11241]	Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients	may	INCOMPLETE_EVIDENCE	[11128]	[11131]	PMC3272870.nxml.gz-223
PMC3272870	PMC3272870.nxml.gz-222	[11069]	[11241]	Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients	differ	ALTERNATIVE_OPTIONS_CONTROVERSY	[11132]	[11138]	PMC3272870.nxml.gz-224
PMC3272870	PMC3272870.nxml.gz-222	[11069]	[11241]	Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients	recommended	FUTURE_WORK	[11150]	[11161]	PMC3272870.nxml.gz-225
PMC3272870	PMC3272870.nxml.gz-222	[11069]	[11241]	Thus doses of D vitamin and calcium supplementation, which may differ from those recommended in normal pregnancy, need to be carefully tailored in thyroidectomised patients	need to be	IMPORTANT_CONSIDERATION	[11183]	[11193]	PMC3272870.nxml.gz-226
PMC3272870	PMC3272870.nxml.gz-227	[11273]	[11414]	Treatment and follow-up of thyroid cancer in pregnant women are the same as in non-pregnant patients except for the use of radioactive iodine	same as	SUPERFICIAL_RELATIONSHIP	[11341]	[11348]	PMC3272870.nxml.gz-228
PMC3272870	PMC3272870.nxml.gz-227	[11273]	[11414]	Treatment and follow-up of thyroid cancer in pregnant women are the same as in non-pregnant patients except for the use of radioactive iodine	as in	INCOMPLETE_EVIDENCE	[11346]	[11351]	PMC3272870.nxml.gz-229
PMC3272870	PMC3272870.nxml.gz-227	[11273]	[11414]	Treatment and follow-up of thyroid cancer in pregnant women are the same as in non-pregnant patients except for the use of radioactive iodine	except for	ALTERNATIVE_OPTIONS_CONTROVERSY	[11374]	[11384]	PMC3272870.nxml.gz-230
PMC3272870	PMC3272870.nxml.gz-237	[11762]	[12000]	Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tumours, which represent the vast majority of tumours diagnosed below 40-45 years of age	Mostly	PROBABLE_UNDERSTANDING	[11762]	[11768]	PMC3272870.nxml.gz-236
PMC3272870	PMC3272870.nxml.gz-237	[11762]	[12000]	Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tumours, which represent the vast majority of tumours diagnosed below 40-45 years of age	usually	INCOMPLETE_EVIDENCE	[11800]	[11807]	PMC3272870.nxml.gz-238
PMC3272870	PMC3272870.nxml.gz-237	[11762]	[12000]	Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tumours, which represent the vast majority of tumours diagnosed below 40-45 years of age	represent	PROBABLE_UNDERSTANDING	[11927]	[11936]	PMC3272870.nxml.gz-239
PMC3272870	PMC3272870.nxml.gz-237	[11762]	[12000]	Mostly diagnosed in young people, DTC usually has a good prognosis with an overall 90-95% long-term disease-free survival for early stage or low risk tumours, which represent the vast majority of tumours diagnosed below 40-45 years of age	majority	PROBABLE_UNDERSTANDING	[11946]	[11954]	PMC3272870.nxml.gz-240
PMC3272870	PMC3272870.nxml.gz-242	[12002]	[12217]	According to the current staging score, DTCs of any dimension, even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age	According to	INCOMPLETE_EVIDENCE	[12002]	[12014]	PMC3272870.nxml.gz-241
PMC3272870	PMC3272870.nxml.gz-242	[12002]	[12217]	According to the current staging score, DTCs of any dimension, even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age	even	ANOMALY_CURIOUS_FINDING	[12065]	[12069]	PMC3272870.nxml.gz-243
PMC3272870	PMC3272870.nxml.gz-242	[12002]	[12217]	According to the current staging score, DTCs of any dimension, even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age	as	PROBABLE_UNDERSTANDING	[12142]	[12144]	PMC3272870.nxml.gz-244
PMC3272870	PMC3272870.nxml.gz-242	[12002]	[12217]	According to the current staging score, DTCs of any dimension, even with nodal invasion, for patients below 45 years of age, are classified as Stage I tumours, and usually pregnant patients are below 45 years of age	usually	INCOMPLETE_EVIDENCE	[12166]	[12173]	PMC3272870.nxml.gz-245
PMC3272870	PMC3272870.nxml.gz-246	[12219]	[12375]	Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identified in most DTC	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[12310]	[12315]	PMC3272870.nxml.gz-247
PMC3272870	PMC3272870.nxml.gz-246	[12219]	[12375]	Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identified in most DTC	have been	INCOMPLETE_EVIDENCE	[12343]	[12352]	PMC3272870.nxml.gz-248
PMC3272870	PMC3272870.nxml.gz-246	[12219]	[12375]	Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identified in most DTC	identified	INCOMPLETE_EVIDENCE	[12353]	[12363]	PMC3272870.nxml.gz-249
PMC3272870	PMC3272870.nxml.gz-246	[12219]	[12375]	Genetic alterations activating a common pathway of the RET-RAS-BRAF signalling cascade and other chromosomal rearrangements have been identified in most DTC	most	PROBABLE_UNDERSTANDING	[12367]	[12371]	PMC3272870.nxml.gz-250
PMC3272870	PMC3272870.nxml.gz-251	[12377]	[12663]	The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage to their genome	may	INCOMPLETE_EVIDENCE	[12454]	[12457]	PMC3272870.nxml.gz-252
PMC3272870	PMC3272870.nxml.gz-251	[12377]	[12663]	The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage to their genome	convincing	IMPORTANT_CONSIDERATION	[12466]	[12476]	PMC3272870.nxml.gz-253
PMC3272870	PMC3272870.nxml.gz-251	[12377]	[12663]	The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage to their genome	proof	PROBABLE_UNDERSTANDING	[12477]	[12482]	PMC3272870.nxml.gz-254
PMC3272870	PMC3272870.nxml.gz-251	[12377]	[12663]	The existence of common genomic changes between DTC and anaplastic carcinoma may provide convincing proof of the multi-step carcinogenesis hypothesis in which cancer cells are produced from well-differentiated benign cells by transformation caused by accumulating damage to their genome	hypothesis	INCOMPLETE_EVIDENCE	[12516]	[12526]	PMC3272870.nxml.gz-255
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	Although	ANOMALY_CURIOUS_FINDING	[12664]	[12672]	PMC3272870.nxml.gz-256
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	reveals	INCOMPLETE_EVIDENCE	[12707]	[12714]	PMC3272870.nxml.gz-258
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	consistent	INCOMPLETE_EVIDENCE	[12722]	[12732]	PMC3272870.nxml.gz-259
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	hypothesis	INCOMPLETE_EVIDENCE	[12752]	[12762]	PMC3272870.nxml.gz-260
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	has been	INCOMPLETE_EVIDENCE	[12763]	[12771]	PMC3272870.nxml.gz-261
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	proposed	INCOMPLETE_EVIDENCE	[12772]	[12780]	PMC3272870.nxml.gz-262
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	can	INCOMPLETE_EVIDENCE	[12788]	[12791]	PMC3272870.nxml.gz-263
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	possibly	INCOMPLETE_EVIDENCE	[12792]	[12800]	PMC3272870.nxml.gz-264
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	explain	PROBABLE_UNDERSTANDING	[12801]	[12808]	PMC3272870.nxml.gz-265
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[12809]	[12814]	PMC3272870.nxml.gz-266
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	according to	INCOMPLETE_EVIDENCE	[12869]	[12881]	PMC3272870.nxml.gz-267
PMC3272870	PMC3272870.nxml.gz-257	[12664]	[13017]	Although gene expression in thyroid cancer reveals highly consistent profiles, a second hypothesis has been proposed, which can possibly explain other "non-RET" tumours: namely foetal cell carcinogenesis, according to which cancer cells are derived from the remnants of foetal thyroid cells, or from stem cells instead of differentiated follicular cells	instead	ALTERNATIVE_OPTIONS_CONTROVERSY	[12975]	[12982]	PMC3272870.nxml.gz-268
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	hypotheses	ALTERNATIVE_OPTIONS_CONTROVERSY	[13024]	[13034]	PMC3272870.nxml.gz-270
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	can	INCOMPLETE_EVIDENCE	[13035]	[13038]	PMC3272870.nxml.gz-271
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	valid	IMPORTANT_CONSIDERATION	[13042]	[13047]	PMC3272870.nxml.gz-272
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	could	INCOMPLETE_EVIDENCE	[13105]	[13110]	PMC3272870.nxml.gz-273
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	explain	PROBABLE_UNDERSTANDING	[13111]	[13118]	PMC3272870.nxml.gz-274
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	some	INCOMPLETE_EVIDENCE	[13119]	[13123]	PMC3272870.nxml.gz-275
PMC3272870	PMC3272870.nxml.gz-269	[13019]	[13161]	Both hypotheses can be valid and coexist, and the second (foetal-cell carcinogenesis) could explain some cases of unusual, rapidly growing DTC	unusual	INCOMPLETE_EVIDENCE	[13133]	[13140]	PMC3272870.nxml.gz-276
PMC3272870	PMC3272870.nxml.gz-277	[13163]	[13366]	Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis	hypotheses	ALTERNATIVE_OPTIONS_CONTROVERSY	[13168]	[13178]	PMC3272870.nxml.gz-278
PMC3272870	PMC3272870.nxml.gz-277	[13163]	[13366]	Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis	would	FUTURE_PREDICTION	[13179]	[13184]	PMC3272870.nxml.gz-279
PMC3272870	PMC3272870.nxml.gz-277	[13163]	[13366]	Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis	suggest	INCOMPLETE_EVIDENCE	[13185]	[13192]	PMC3272870.nxml.gz-280
PMC3272870	PMC3272870.nxml.gz-277	[13163]	[13366]	Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis	though	ANOMALY_CURIOUS_FINDING	[13295]	[13301]	PMC3272870.nxml.gz-281
PMC3272870	PMC3272870.nxml.gz-277	[13163]	[13366]	Both hypotheses would suggest a higher thyroid neoplasm proliferation in stimulated thyroid tissue during pregnancy or adolescence, though even in growing tissues these cancers show a very good prognosis	even	ANOMALY_CURIOUS_FINDING	[13302]	[13306]	PMC3272870.nxml.gz-282
PMC3272870	PMC3272870.nxml.gz-283	[13368]	[13450]	The best treatment for nearly all identified malignant thyroid neoplasm is surgery	best	IMPORTANT_CONSIDERATION	[13372]	[13376]	PMC3272870.nxml.gz-284
PMC3272870	PMC3272870.nxml.gz-283	[13368]	[13450]	The best treatment for nearly all identified malignant thyroid neoplasm is surgery	nearly all	PROBABLE_UNDERSTANDING	[13391]	[13401]	PMC3272870.nxml.gz-285
PMC3272870	PMC3272870.nxml.gz-288	[13564]	[13655]	Considerable controversy still exists over the optimal extent of primary surgical resection	Considerable	ANOMALY_CURIOUS_FINDING	[13564]	[13576]	PMC3272870.nxml.gz-287
PMC3272870	PMC3272870.nxml.gz-288	[13564]	[13655]	Considerable controversy still exists over the optimal extent of primary surgical resection	controversy	ALTERNATIVE_OPTIONS_CONTROVERSY	[13577]	[13588]	PMC3272870.nxml.gz-289
PMC3272870	PMC3272870.nxml.gz-288	[13564]	[13655]	Considerable controversy still exists over the optimal extent of primary surgical resection	still	IMPORTANT_CONSIDERATION	[13589]	[13594]	PMC3272870.nxml.gz-290
PMC3272870	PMC3272870.nxml.gz-292	[13754]	[14009]	As nodal spread is relatively common, initial surgical exploration should include careful examination of the central compartment nodes (paratracheal and tracheoesophageal) as well as dissection of clinically suspicious nodes for frozen section examination	As	PROBABLE_UNDERSTANDING	[13754]	[13756]	PMC3272870.nxml.gz-291
PMC3272870	PMC3272870.nxml.gz-292	[13754]	[14009]	As nodal spread is relatively common, initial surgical exploration should include careful examination of the central compartment nodes (paratracheal and tracheoesophageal) as well as dissection of clinically suspicious nodes for frozen section examination	should	FUTURE_WORK	[13821]	[13827]	PMC3272870.nxml.gz-293
PMC3272870	PMC3272870.nxml.gz-294	[14011]	[14141]	Nodes in the jugular chains should also be carefully examined with US before surgery and, when suspicious, FNAB should be obtained	should	FUTURE_WORK	[14039]	[14045]	PMC3272870.nxml.gz-295
PMC3272870	PMC3272870.nxml.gz-294	[14011]	[14141]	Nodes in the jugular chains should also be carefully examined with US before surgery and, when suspicious, FNAB should be obtained	should be	FUTURE_WORK	[14123]	[14132]	PMC3272870.nxml.gz-297
PMC3272870	PMC3272870.nxml.gz-299	[14143]	[14248]	If nodal involvement is confirmed, total thyroidectomy and modified radical neck dissection are indicated	If	ALTERNATIVE_OPTIONS_CONTROVERSY	[14143]	[14145]	PMC3272870.nxml.gz-298
PMC3272870	PMC3272870.nxml.gz-299	[14143]	[14248]	If nodal involvement is confirmed, total thyroidectomy and modified radical neck dissection are indicated	confirmed	INCOMPLETE_EVIDENCE	[14167]	[14176]	PMC3272870.nxml.gz-300
PMC3272870	PMC3272870.nxml.gz-299	[14143]	[14248]	If nodal involvement is confirmed, total thyroidectomy and modified radical neck dissection are indicated	indicated	INCOMPLETE_EVIDENCE	[14239]	[14248]	PMC3272870.nxml.gz-301
PMC3272870	PMC3272870.nxml.gz-302	[14269]	[14609]	Thyroid hormones – Endocrine therapy: post-operative oral administration of supraphysiologic oral doses of levothyroxine are used assuming that the suppression of endogenous production of TSH deprives TSH-dependent DTC cells of an important growth-promoting influence and the goal for basal serum TSH should be in the 0.1 to 0.4 mIU/L range	assuming	ALTERNATIVE_OPTIONS_CONTROVERSY	[14399]	[14407]	PMC3272870.nxml.gz-304
PMC3272870	PMC3272870.nxml.gz-302	[14269]	[14609]	Thyroid hormones – Endocrine therapy: post-operative oral administration of supraphysiologic oral doses of levothyroxine are used assuming that the suppression of endogenous production of TSH deprives TSH-dependent DTC cells of an important growth-promoting influence and the goal for basal serum TSH should be in the 0.1 to 0.4 mIU/L range	goal	IMPORTANT_CONSIDERATION	[14545]	[14549]	PMC3272870.nxml.gz-307
PMC3272870	PMC3272870.nxml.gz-302	[14269]	[14609]	Thyroid hormones – Endocrine therapy: post-operative oral administration of supraphysiologic oral doses of levothyroxine are used assuming that the suppression of endogenous production of TSH deprives TSH-dependent DTC cells of an important growth-promoting influence and the goal for basal serum TSH should be in the 0.1 to 0.4 mIU/L range	should be	FUTURE_WORK	[14570]	[14579]	PMC3272870.nxml.gz-308
PMC3272870	PMC3272870.nxml.gz-309	[14867]	[15191]	This adjunctive therapy is supposed to destroy occult microscopic carcinoma within the thyroid remnant by being actively trapped both by normal and pathological thyroid cells, and to facilitate follow-up because serum thyroglobulin (HTG) measurements are more reliable after the destruction of residual normal thyroid tissue	supposed to	PROBABLE_UNDERSTANDING	[14894]	[14905]	PMC3272870.nxml.gz-311
PMC3272870	PMC3272870.nxml.gz-309	[14867]	[15191]	This adjunctive therapy is supposed to destroy occult microscopic carcinoma within the thyroid remnant by being actively trapped both by normal and pathological thyroid cells, and to facilitate follow-up because serum thyroglobulin (HTG) measurements are more reliable after the destruction of residual normal thyroid tissue	because	PROBABLE_UNDERSTANDING	[15071]	[15078]	PMC3272870.nxml.gz-312
PMC3272870	PMC3272870.nxml.gz-309	[14867]	[15191]	This adjunctive therapy is supposed to destroy occult microscopic carcinoma within the thyroid remnant by being actively trapped both by normal and pathological thyroid cells, and to facilitate follow-up because serum thyroglobulin (HTG) measurements are more reliable after the destruction of residual normal thyroid tissue	reliable	IMPORTANT_CONSIDERATION	[15127]	[15135]	PMC3272870.nxml.gz-313
PMC3272870	PMC3272870.nxml.gz-317	[15306]	[15402]	All patients should undergo neck ultrasound and serum assay for HTG, HTG antibodies, fT4 and TSH	should	IMPORTANT_CONSIDERATION	[15319]	[15325]	PMC3272870.nxml.gz-319
PMC3272870	PMC3272870.nxml.gz-320	[15404]	[15681]	For thyroidectomized high-risk, non-pregnant patients, I-131 scan is also indicated, and serum HTG measurements – performed both with thyroxine deprivation or under rTSH (recombinant human TSH) stimulation – is a useful and reliable marker of disease progression or persistence	indicated	IMPORTANT_CONSIDERATION	[15478]	[15487]	PMC3272870.nxml.gz-321
PMC3272870	PMC3272870.nxml.gz-320	[15404]	[15681]	For thyroidectomized high-risk, non-pregnant patients, I-131 scan is also indicated, and serum HTG measurements – performed both with thyroxine deprivation or under rTSH (recombinant human TSH) stimulation – is a useful and reliable marker of disease progression or persistence	reliable	IMPORTANT_CONSIDERATION	[15628]	[15636]	PMC3272870.nxml.gz-322
PMC3272870	PMC3272870.nxml.gz-320	[15404]	[15681]	For thyroidectomized high-risk, non-pregnant patients, I-131 scan is also indicated, and serum HTG measurements – performed both with thyroxine deprivation or under rTSH (recombinant human TSH) stimulation – is a useful and reliable marker of disease progression or persistence	marker	SUPERFICIAL_RELATIONSHIP	[15637]	[15643]	PMC3272870.nxml.gz-323
PMC3272870	PMC3272870.nxml.gz-325	[15683]	[15970]	In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence41-45	In our experience	PROBABLE_UNDERSTANDING	[15683]	[15700]	PMC3272870.nxml.gz-324
PMC3272870	PMC3272870.nxml.gz-325	[15683]	[15970]	In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence41-45	best	IMPORTANT_CONSIDERATION	[15706]	[15710]	PMC3272870.nxml.gz-326
PMC3272870	PMC3272870.nxml.gz-325	[15683]	[15970]	In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence41-45	without question	PROBABLE_UNDERSTANDING	[15768]	[15784]	PMC3272870.nxml.gz-328
PMC3272870	PMC3272870.nxml.gz-325	[15683]	[15970]	In our experience, the best follow-up method to detect loco-regional recurrences is, without question, neck sonography, followed by a meticulous physical examination by experienced personnel and, when indicated, ultrasound-guided FNA to confirm clinical suspicion of neck recurrence41-45	when indicated	ALTERNATIVE_OPTIONS_CONTROVERSY	[15879]	[15893]	PMC3272870.nxml.gz-329
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	approximately	INCOMPLETE_EVIDENCE	[16136]	[16149]	PMC3272870.nxml.gz-333
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	although	ANOMALY_CURIOUS_FINDING	[16176]	[16184]	PMC3272870.nxml.gz-334
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	there are no	FULL_UNKNOWN	[16185]	[16197]	PMC3272870.nxml.gz-335
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	because	PROBLEM_COMPLICATION	[16247]	[16254]	PMC3272870.nxml.gz-336
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	variations	DIFFICULT_TASK	[16279]	[16289]	PMC3272870.nxml.gz-337
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	mainly	PROBABLE_UNDERSTANDING	[16291]	[16297]	PMC3272870.nxml.gz-338
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	due to	PROBLEM_COMPLICATION	[16298]	[16304]	PMC3272870.nxml.gz-339
PMC3272870	PMC3272870.nxml.gz-332	[16083]	[16325]	Medullary carcinoma of the thyroid (MTC) constitutes approximately 5-10% of thyroid cancers, although there are no precise figures for incidence and survival rates because of the large geographic variations, mainly due to its familial pattern	pattern	SUPERFICIAL_RELATIONSHIP	[16318]	[16325]	PMC3272870.nxml.gz-340
PMC3272870	PMC3272870.nxml.gz-342	[16327]	[16556]	Although uncommon, MTC is interesting because of its biochemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), and in the non-MEN forms	Although	ANOMALY_CURIOUS_FINDING	[16327]	[16335]	PMC3272870.nxml.gz-341
PMC3272870	PMC3272870.nxml.gz-342	[16327]	[16556]	Although uncommon, MTC is interesting because of its biochemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), and in the non-MEN forms	uncommon	INCOMPLETE_EVIDENCE	[16336]	[16344]	PMC3272870.nxml.gz-343
PMC3272870	PMC3272870.nxml.gz-342	[16327]	[16556]	Although uncommon, MTC is interesting because of its biochemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), and in the non-MEN forms	interesting	ANOMALY_CURIOUS_FINDING	[16353]	[16364]	PMC3272870.nxml.gz-344
PMC3272870	PMC3272870.nxml.gz-342	[16327]	[16556]	Although uncommon, MTC is interesting because of its biochemical and genetic features and clinical association, both in autosomal-dominant inherited syndromes with incomplete penetrance (MEN IIA and IIB), and in the non-MEN forms	association	SUPERFICIAL_RELATIONSHIP	[16426]	[16437]	PMC3272870.nxml.gz-345
PMC3272870	PMC3272870.nxml.gz-346	[16558]	[16602]	Familial cases account for about 30% of MTCs	account for	PROBABLE_UNDERSTANDING	[16573]	[16584]	PMC3272870.nxml.gz-347
PMC3272870	PMC3272870.nxml.gz-346	[16558]	[16602]	Familial cases account for about 30% of MTCs	about	INCOMPLETE_EVIDENCE	[16585]	[16590]	PMC3272870.nxml.gz-348
PMC3272870	PMC3272870.nxml.gz-352	[16751]	[16846]	First, patients with MTC should always be suspected of carrying the genetic form of the disease	should	IMPORTANT_CONSIDERATION	[16776]	[16782]	PMC3272870.nxml.gz-355
PMC3272870	PMC3272870.nxml.gz-352	[16751]	[16846]	First, patients with MTC should always be suspected of carrying the genetic form of the disease	suspected	PROBABLE_UNDERSTANDING	[16793]	[16802]	PMC3272870.nxml.gz-356
PMC3272870	PMC3272870.nxml.gz-357	[16848]	[16996]	Secondly, the possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy	possible	INCOMPLETE_EVIDENCE	[16862]	[16870]	PMC3272870.nxml.gz-358
PMC3272870	PMC3272870.nxml.gz-357	[16848]	[16996]	Secondly, the possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy	associated	SUPERFICIAL_RELATIONSHIP	[16883]	[16893]	PMC3272870.nxml.gz-359
PMC3272870	PMC3272870.nxml.gz-357	[16848]	[16996]	Secondly, the possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy	should be	FUTURE_WORK	[16932]	[16941]	PMC3272870.nxml.gz-360
PMC3272870	PMC3272870.nxml.gz-357	[16848]	[16996]	Secondly, the possible presence of associated conditions, such as pheochromocytoma, should be recognized before submitting patients to thyroidectomy	recognized	PROBABLE_UNDERSTANDING	[16942]	[16952]	PMC3272870.nxml.gz-362
PMC3272870	PMC3272870.nxml.gz-363	[16998]	[17116]	Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge	since	PROBLEM_COMPLICATION	[17006]	[17011]	PMC3272870.nxml.gz-364
PMC3272870	PMC3272870.nxml.gz-363	[16998]	[17116]	Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge	variable	DIFFICULT_TASK	[17055]	[17063]	PMC3272870.nxml.gz-365
PMC3272870	PMC3272870.nxml.gz-363	[16998]	[17116]	Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge	represents	SUPERFICIAL_RELATIONSHIP	[17077]	[17087]	PMC3272870.nxml.gz-366
PMC3272870	PMC3272870.nxml.gz-363	[16998]	[17116]	Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge	true	PROBABLE_UNDERSTANDING	[17090]	[17094]	PMC3272870.nxml.gz-367
PMC3272870	PMC3272870.nxml.gz-363	[16998]	[17116]	Lastly, since the clinical behaviour of MTC is extremely variable, this tumour represents a true therapeutic challenge	challenge	DIFFICULT_TASK	[17107]	[17116]	PMC3272870.nxml.gz-368
PMC3272870	PMC3272870.nxml.gz-369	[17118]	[17323]	MTC arises from C cells secreting calcitonin, a 32-amino acid peptide. Calcitonin is the most clinically useful biochemical marker for these tumours, and C cell hyperplasia represents a pre-cancerous stage	represents	SUPERFICIAL_RELATIONSHIP	[17291]	[17301]	PMC3272870.nxml.gz-370
PMC3272870	PMC3272870.nxml.gz-371	[17325]	[17476]	These neuroendocrine cells are believed to be of neural crest origin, thus having a separate lineage from the endoderm-derived follicular thyroid cells	believed	INCOMPLETE_EVIDENCE	[17356]	[17364]	PMC3272870.nxml.gz-372
PMC3272870	PMC3272870.nxml.gz-371	[17325]	[17476]	These neuroendocrine cells are believed to be of neural crest origin, thus having a separate lineage from the endoderm-derived follicular thyroid cells	thus	PROBABLE_UNDERSTANDING	[17395]	[17399]	PMC3272870.nxml.gz-373
PMC3272870	PMC3272870.nxml.gz-375	[17478]	[17889]	For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease	For this reason	PROBABLE_UNDERSTANDING	[17478]	[17493]	PMC3272870.nxml.gz-374
PMC3272870	PMC3272870.nxml.gz-375	[17478]	[17889]	For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[17644]	[17649]	PMC3272870.nxml.gz-376
PMC3272870	PMC3272870.nxml.gz-375	[17478]	[17889]	For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease	reflect	SUPERFICIAL_RELATIONSHIP	[17675]	[17682]	PMC3272870.nxml.gz-377
PMC3272870	PMC3272870.nxml.gz-375	[17478]	[17889]	For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease	implicated	SUPERFICIAL_RELATIONSHIP	[17730]	[17740]	PMC3272870.nxml.gz-378
PMC3272870	PMC3272870.nxml.gz-375	[17478]	[17889]	For this reason, in addition to calcitonin-gene products, such as calcitonin CGRP (calcitonin-generelated- peptide) and C-CAP (katacalcin), MTC cells express several other biochemical markers that reflect the features of diffuse neuroendocrine system, implicated in the pathogenesis of the symptoms (flushing, diarrhoea, carcinoid syndrome or Cushing's syndrome) that may occur in patients with advanced disease	may	INCOMPLETE_EVIDENCE	[17846]	[17849]	PMC3272870.nxml.gz-379
PMC3272870	PMC3272870.nxml.gz-380	[17891]	[18072]	These cells can also produce prostaglandins and other neuroendocrine markers such as chromogranin A, sometimes used together with calcitonin and CEA in MTC patients during follow-up	can	INCOMPLETE_EVIDENCE	[17903]	[17906]	PMC3272870.nxml.gz-381
PMC3272870	PMC3272870.nxml.gz-380	[17891]	[18072]	These cells can also produce prostaglandins and other neuroendocrine markers such as chromogranin A, sometimes used together with calcitonin and CEA in MTC patients during follow-up	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[17939]	[17944]	PMC3272870.nxml.gz-382
PMC3272870	PMC3272870.nxml.gz-380	[17891]	[18072]	These cells can also produce prostaglandins and other neuroendocrine markers such as chromogranin A, sometimes used together with calcitonin and CEA in MTC patients during follow-up	sometimes	INCOMPLETE_EVIDENCE	[17992]	[18001]	PMC3272870.nxml.gz-383
PMC3272870	PMC3272870.nxml.gz-384	[18074]	[18311]	When dealing with MTC, we should always bear in mind that these patients may be the index-case for one of the familial forms of the disease: presymptomatic screening of relatives of MTC patients enables early diagnosis of this malignancy	should	IMPORTANT_CONSIDERATION	[18100]	[18106]	PMC3272870.nxml.gz-386
PMC3272870	PMC3272870.nxml.gz-384	[18074]	[18311]	When dealing with MTC, we should always bear in mind that these patients may be the index-case for one of the familial forms of the disease: presymptomatic screening of relatives of MTC patients enables early diagnosis of this malignancy	bear in mind	IMPORTANT_CONSIDERATION	[18114]	[18126]	PMC3272870.nxml.gz-387
PMC3272870	PMC3272870.nxml.gz-384	[18074]	[18311]	When dealing with MTC, we should always bear in mind that these patients may be the index-case for one of the familial forms of the disease: presymptomatic screening of relatives of MTC patients enables early diagnosis of this malignancy	may be	INCOMPLETE_EVIDENCE	[18147]	[18153]	PMC3272870.nxml.gz-388
PMC3272870	PMC3272870.nxml.gz-389	[18313]	[18470]	Early diagnosis rather than more extensive surgery may improve survival and reduce recurrences, mostly in the MEN IIB form of MTC, which is highly aggressive	rather	ALTERNATIVE_OPTIONS_CONTROVERSY	[18329]	[18335]	PMC3272870.nxml.gz-390
PMC3272870	PMC3272870.nxml.gz-389	[18313]	[18470]	Early diagnosis rather than more extensive surgery may improve survival and reduce recurrences, mostly in the MEN IIB form of MTC, which is highly aggressive	may	INCOMPLETE_EVIDENCE	[18364]	[18367]	PMC3272870.nxml.gz-391
PMC3272870	PMC3272870.nxml.gz-389	[18313]	[18470]	Early diagnosis rather than more extensive surgery may improve survival and reduce recurrences, mostly in the MEN IIB form of MTC, which is highly aggressive	mostly	PROBABLE_UNDERSTANDING	[18409]	[18415]	PMC3272870.nxml.gz-392
PMC3272870	PMC3272870.nxml.gz-395	[18635]	[18889]	In inherited forms, the initial germline mutation produces multiple foci of cells – the so-called C-cell hyperplasia – that are susceptible to tumour formation, and each MTC is the result of a second cell transformation in one of these susceptible clones	so-called	INCOMPLETE_EVIDENCE	[18723]	[18732]	PMC3272870.nxml.gz-396
PMC3272870	PMC3272870.nxml.gz-397	[18891]	[18982]	Primary MTC lesions become visible at echography as solid masses, often with calcifications	become visible	INCOMPLETE_EVIDENCE	[18911]	[18925]	PMC3272870.nxml.gz-398
PMC3272870	PMC3272870.nxml.gz-397	[18891]	[18982]	Primary MTC lesions become visible at echography as solid masses, often with calcifications	often	PROBABLE_UNDERSTANDING	[18957]	[18962]	PMC3272870.nxml.gz-399
PMC3272870	PMC3272870.nxml.gz-400	[18984]	[19158]	Fine needle aspiration shows a mixture of round, polyhedral and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid	shows	INCOMPLETE_EVIDENCE	[19007]	[19012]	PMC3272870.nxml.gz-401
PMC3272870	PMC3272870.nxml.gz-400	[18984]	[19158]	Fine needle aspiration shows a mixture of round, polyhedral and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid	may	INCOMPLETE_EVIDENCE	[19074]	[19077]	PMC3272870.nxml.gz-402
PMC3272870	PMC3272870.nxml.gz-400	[18984]	[19158]	Fine needle aspiration shows a mixture of round, polyhedral and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid	seem	ANOMALY_CURIOUS_FINDING	[19078]	[19082]	PMC3272870.nxml.gz-403
PMC3272870	PMC3272870.nxml.gz-400	[18984]	[19158]	Fine needle aspiration shows a mixture of round, polyhedral and spindle-shaped cells that may seem undifferentiated, and look like a variable amount of extra-cellular amyloid	look like	SUPERFICIAL_RELATIONSHIP	[19105]	[19114]	PMC3272870.nxml.gz-404
PMC3272870	PMC3272870.nxml.gz-416	[19538]	[19608]	MTC is somewhat more aggressive than papillary or follicular carcinoma	somewhat	INCOMPLETE_EVIDENCE	[19545]	[19553]	PMC3272870.nxml.gz-417
PMC3272870	PMC3272870.nxml.gz-418	[19610]	[19776]	It locally extends into lymph nodes and into the surrounding muscles and trachea, and may invade lymphatic and blood vessels and metastasize in lungs, bones and liver	may	INCOMPLETE_EVIDENCE	[19696]	[19699]	PMC3272870.nxml.gz-419
PMC3272870	PMC3272870.nxml.gz-420	[19778]	[19922]	Sporadic MTC tumours are often monolateral with a single localization, while familial forms are mostly bilateral and often multifocal or diffuse	often	PROBABLE_UNDERSTANDING	[19803]	[19808]	PMC3272870.nxml.gz-421
PMC3272870	PMC3272870.nxml.gz-420	[19778]	[19922]	Sporadic MTC tumours are often monolateral with a single localization, while familial forms are mostly bilateral and often multifocal or diffuse	while	ALTERNATIVE_OPTIONS_CONTROVERSY	[19849]	[19854]	PMC3272870.nxml.gz-422
PMC3272870	PMC3272870.nxml.gz-420	[19778]	[19922]	Sporadic MTC tumours are often monolateral with a single localization, while familial forms are mostly bilateral and often multifocal or diffuse	mostly	PROBABLE_UNDERSTANDING	[19874]	[19880]	PMC3272870.nxml.gz-423
PMC3272870	PMC3272870.nxml.gz-420	[19778]	[19922]	Sporadic MTC tumours are often monolateral with a single localization, while familial forms are mostly bilateral and often multifocal or diffuse	often	PROBABLE_UNDERSTANDING	[19895]	[19900]	PMC3272870.nxml.gz-424
PMC3272870	PMC3272870.nxml.gz-425	[19924]	[20008]	For these reasons, total thyroidectomy appears to be the appropriate approach to MTC	reasons	PROBABLE_UNDERSTANDING	[19934]	[19941]	PMC3272870.nxml.gz-426
PMC3272870	PMC3272870.nxml.gz-425	[19924]	[20008]	For these reasons, total thyroidectomy appears to be the appropriate approach to MTC	appears to be	ANOMALY_CURIOUS_FINDING	[19963]	[19976]	PMC3272870.nxml.gz-427
PMC3272870	PMC3272870.nxml.gz-425	[19924]	[20008]	For these reasons, total thyroidectomy appears to be the appropriate approach to MTC	appropriate	IMPORTANT_CONSIDERATION	[19981]	[19992]	PMC3272870.nxml.gz-428
PMC3272870	PMC3272870.nxml.gz-429	[20010]	[20171]	Central neck and upper mediastinum clearance and, in addition, mono or bilateral node dissection (depending on the extent of nodal involvement) is also advisable	advisable	IMPORTANT_CONSIDERATION	[20162]	[20171]	PMC3272870.nxml.gz-431
PMC3272870	PMC3272870.nxml.gz-432	[20173]	[20380]	The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage	appropriate	IMPORTANT_CONSIDERATION	[20182]	[20193]	PMC3272870.nxml.gz-433
PMC3272870	PMC3272870.nxml.gz-432	[20173]	[20380]	The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage	still	IMPORTANT_CONSIDERATION	[20231]	[20236]	PMC3272870.nxml.gz-434
PMC3272870	PMC3272870.nxml.gz-432	[20173]	[20380]	The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage	debate	ALTERNATIVE_OPTIONS_CONTROVERSY	[20249]	[20255]	PMC3272870.nxml.gz-435
PMC3272870	PMC3272870.nxml.gz-432	[20173]	[20380]	The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[20257]	[20260]	PMC3272870.nxml.gz-436
PMC3272870	PMC3272870.nxml.gz-432	[20173]	[20380]	The most appropriate treatment for clinical N0 tumours is still a matter of debate, but most surgeons prefer prophylactic node dissection because MTC metastasize in regional lymph nodes at a very early stage	because	PROBABLE_UNDERSTANDING	[20311]	[20318]	PMC3272870.nxml.gz-438
PMC3272870	PMC3272870.nxml.gz-439	[20382]	[20500]	Surgery is the only treatment which is considered potentially curative for metastatic or recurrent medullary carcinoma	only	INCOMPLETE_EVIDENCE	[20397]	[20401]	PMC3272870.nxml.gz-440
PMC3272870	PMC3272870.nxml.gz-439	[20382]	[20500]	Surgery is the only treatment which is considered potentially curative for metastatic or recurrent medullary carcinoma	is considered	INCOMPLETE_EVIDENCE	[20418]	[20431]	PMC3272870.nxml.gz-441
PMC3272870	PMC3272870.nxml.gz-439	[20382]	[20500]	Surgery is the only treatment which is considered potentially curative for metastatic or recurrent medullary carcinoma	potentially	INCOMPLETE_EVIDENCE	[20432]	[20443]	PMC3272870.nxml.gz-442
PMC3272870	PMC3272870.nxml.gz-443	[20502]	[20598]	The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive	role	SUPERFICIAL_RELATIONSHIP	[20506]	[20510]	PMC3272870.nxml.gz-444
PMC3272870	PMC3272870.nxml.gz-443	[20502]	[20598]	The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive	controversial	ALTERNATIVE_OPTIONS_CONTROVERSY	[20530]	[20543]	PMC3272870.nxml.gz-445
PMC3272870	PMC3272870.nxml.gz-443	[20502]	[20598]	The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive	as	PROBABLE_UNDERSTANDING	[20544]	[20546]	PMC3272870.nxml.gz-446
PMC3272870	PMC3272870.nxml.gz-443	[20502]	[20598]	The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive	generally	PROBABLE_UNDERSTANDING	[20554]	[20563]	PMC3272870.nxml.gz-447
PMC3272870	PMC3272870.nxml.gz-443	[20502]	[20598]	The role of radiotherapy is controversial as MTC is generally not believed to be radio-sensitive	believed	INCOMPLETE_EVIDENCE	[20568]	[20576]	PMC3272870.nxml.gz-448
PMC3272870	PMC3272870.nxml.gz-449	[20600]	[20731]	Therapy with long-acting somatostatin analogues has been tested in metastatic disease, with some positive benefots in most patients	has been	INCOMPLETE_EVIDENCE	[20648]	[20656]	PMC3272870.nxml.gz-450
PMC3272870	PMC3272870.nxml.gz-449	[20600]	[20731]	Therapy with long-acting somatostatin analogues has been tested in metastatic disease, with some positive benefots in most patients	some	INCOMPLETE_EVIDENCE	[20692]	[20696]	PMC3272870.nxml.gz-451
PMC3272870	PMC3272870.nxml.gz-454	[20816]	[20882]	No reliably effective chemotherapeutic regimen has been identified	No ... identified	FULL_UNKNOWN	[20816, 20872]	[20818, 20882]	PMC3272870.nxml.gz-457
PMC3272870	PMC3272870.nxml.gz-454	[20816]	[20882]	No reliably effective chemotherapeutic regimen has been identified	has been	INCOMPLETE_EVIDENCE	[20863]	[20871]	PMC3272870.nxml.gz-459
PMC3272870	PMC3272870.nxml.gz-462	[20884]	[20992]	New drugs with anti-angiogenetic, anti-tyrosine kinase and anti-VEGF effects are currently under observation	New	FULL_UNKNOWN	[20884]	[20887]	PMC3272870.nxml.gz-461
PMC3272870	PMC3272870.nxml.gz-462	[20884]	[20992]	New drugs with anti-angiogenetic, anti-tyrosine kinase and anti-VEGF effects are currently under observation	effects	SUPERFICIAL_RELATIONSHIP	[20953]	[20960]	PMC3272870.nxml.gz-463
PMC3272870	PMC3272870.nxml.gz-462	[20884]	[20992]	New drugs with anti-angiogenetic, anti-tyrosine kinase and anti-VEGF effects are currently under observation	under observation	INCOMPLETE_EVIDENCE	[20975]	[20992]	PMC3272870.nxml.gz-464
PMC3272870	PMC3272870.nxml.gz-466	[20994]	[21260]	In conclusion, there are several ways to expedite the diagnosis of MTC and to follow-up patients after surgery: biochemical markers (e.g. CEA, calcitonin, katacalcin, chromogranin-A according to tumour staining), and scanning with specific ligands such as octreotide	conclusion	INCOMPLETE_EVIDENCE	[20997]	[21007]	PMC3272870.nxml.gz-467
PMC3272870	PMC3272870.nxml.gz-466	[20994]	[21260]	In conclusion, there are several ways to expedite the diagnosis of MTC and to follow-up patients after surgery: biochemical markers (e.g. CEA, calcitonin, katacalcin, chromogranin-A according to tumour staining), and scanning with specific ligands such as octreotide	several ways	ALTERNATIVE_OPTIONS_CONTROVERSY	[21019]	[21031]	PMC3272870.nxml.gz-30899
PMC3272870	PMC3272870.nxml.gz-470	[21262]	[21367]	Furthermore, there are new therapeutic approaches under validation for advanced or recurrent disease46-48	new	FULL_UNKNOWN	[21285]	[21288]	PMC3272870.nxml.gz-471
PMC3272870	PMC3272870.nxml.gz-470	[21262]	[21367]	Furthermore, there are new therapeutic approaches under validation for advanced or recurrent disease46-48	under validation	INCOMPLETE_EVIDENCE	[21312]	[21328]	PMC3272870.nxml.gz-472
PMC3272870	PMC3272870.nxml.gz-474	[21369]	[21555]	Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy	often	PROBABLE_UNDERSTANDING	[21402]	[21407]	PMC3272870.nxml.gz-475
PMC3272870	PMC3272870.nxml.gz-474	[21369]	[21555]	Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy	misdiagnosed	PROBLEM_COMPLICATION	[21408]	[21420]	PMC3272870.nxml.gz-476
PMC3272870	PMC3272870.nxml.gz-474	[21369]	[21555]	Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy	because	PROBLEM_COMPLICATION	[21421]	[21428]	PMC3272870.nxml.gz-477
PMC3272870	PMC3272870.nxml.gz-474	[21369]	[21555]	Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[21482]	[21485]	PMC3272870.nxml.gz-478
PMC3272870	PMC3272870.nxml.gz-474	[21369]	[21555]	Thyroid nodules in pregnancy are often misdiagnosed because of physiological thyroid increases during pregnancy, but clinical and ultrasound findings are sufficient to suspect malignancy	suspect	PROBABLE_UNDERSTANDING	[21537]	[21544]	PMC3272870.nxml.gz-480
PMC3272870	PMC3272870.nxml.gz-481	[21557]	[21782]	Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions	seem	ANOMALY_CURIOUS_FINDING	[21636]	[21640]	PMC3272870.nxml.gz-482
PMC3272870	PMC3272870.nxml.gz-481	[21557]	[21782]	Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions	reliable	IMPORTANT_CONSIDERATION	[21646]	[21654]	PMC3272870.nxml.gz-483
PMC3272870	PMC3272870.nxml.gz-481	[21557]	[21782]	Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[21660]	[21665]	PMC3272870.nxml.gz-484
PMC3272870	PMC3272870.nxml.gz-481	[21557]	[21782]	Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions	detecting	INCOMPLETE_EVIDENCE	[21680]	[21689]	PMC3272870.nxml.gz-485
PMC3272870	PMC3272870.nxml.gz-481	[21557]	[21782]	Skilled examiners and good quality images with grey-scale and power Doppler US seem more reliable than other techniques in detecting and differentiating malignant and benign solid thyroid nodules, especially for small lesions	differentiating	INCOMPLETE_EVIDENCE	[21694]	[21709]	PMC3272870.nxml.gz-486
PMC3272870	PMC3272870.nxml.gz-488	[21784]	[21925]	Even during pregnancy, US guided fine-needle aspiration biopsy (FNA) is the investigation of choice, thanks to its reliability and safety1926	Even	ANOMALY_CURIOUS_FINDING	[21784]	[21788]	PMC3272870.nxml.gz-487
PMC3272870	PMC3272870.nxml.gz-488	[21784]	[21925]	Even during pregnancy, US guided fine-needle aspiration biopsy (FNA) is the investigation of choice, thanks to its reliability and safety1926	of choice	IMPORTANT_CONSIDERATION	[21874]	[21883]	PMC3272870.nxml.gz-489
PMC3272870	PMC3272870.nxml.gz-488	[21784]	[21925]	Even during pregnancy, US guided fine-needle aspiration biopsy (FNA) is the investigation of choice, thanks to its reliability and safety1926	reliability	IMPORTANT_CONSIDERATION	[21899]	[21910]	PMC3272870.nxml.gz-490
PMC3272870	PMC3272870.nxml.gz-488	[21784]	[21925]	Even during pregnancy, US guided fine-needle aspiration biopsy (FNA) is the investigation of choice, thanks to its reliability and safety1926	safety	IMPORTANT_CONSIDERATION	[21915]	[21921]	PMC3272870.nxml.gz-491
PMC3272870	PMC3272870.nxml.gz-492	[21927]	[22191]	Papillary thyroid cancer is the most common histological type detected in pregnant women, and in most series 90% to 95% of thyroid carcinoma diagnosed are Stage I disease, with the majority found in the first trimester of pregnancy during the first antenatal visit	most common	IMPORTANT_CONSIDERATION	[21959]	[21970]	PMC3272870.nxml.gz-493
PMC3272870	PMC3272870.nxml.gz-492	[21927]	[22191]	Papillary thyroid cancer is the most common histological type detected in pregnant women, and in most series 90% to 95% of thyroid carcinoma diagnosed are Stage I disease, with the majority found in the first trimester of pregnancy during the first antenatal visit	majority	PROBABLE_UNDERSTANDING	[22108]	[22116]	PMC3272870.nxml.gz-496
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	may be	INCOMPLETE_EVIDENCE	[22230]	[22236]	PMC3272870.nxml.gz-499
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	important	IMPORTANT_CONSIDERATION	[22240]	[22249]	PMC3272870.nxml.gz-500
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	factor	SUPERFICIAL_RELATIONSHIP	[22250]	[22256]	PMC3272870.nxml.gz-501
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	favouring	PROBABLE_UNDERSTANDING	[22257]	[22266]	PMC3272870.nxml.gz-502
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	as	PROBABLE_UNDERSTANDING	[22286]	[22288]	PMC3272870.nxml.gz-503
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	mostly	PROBABLE_UNDERSTANDING	[22327]	[22333]	PMC3272870.nxml.gz-504
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	whereas	ALTERNATIVE_OPTIONS_CONTROVERSY	[22359]	[22366]	PMC3272870.nxml.gz-505
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	less common	INCOMPLETE_EVIDENCE	[22367]	[22378]	PMC3272870.nxml.gz-506
PMC3272870	PMC3272870.nxml.gz-498	[22193]	[22477]	The predominance of papillary cancer may be an important factor favouring localized disease, as these cancers metastasize slowly, and mostly in the lymphatic system, whereas less common follicular cancers tend to spread via angio-invasion with a higher frequency of distant metastasis	tend	SUPERFICIAL_RELATIONSHIP	[22398]	[22402]	PMC3272870.nxml.gz-508
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	Although	ANOMALY_CURIOUS_FINDING	[22479]	[22487]	PMC3272870.nxml.gz-509
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	may	INCOMPLETE_EVIDENCE	[22520]	[22523]	PMC3272870.nxml.gz-511
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	since	PROBLEM_COMPLICATION	[22548]	[22553]	PMC3272870.nxml.gz-512
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	factors	SUPERFICIAL_RELATIONSHIP	[22563]	[22570]	PMC3272870.nxml.gz-513
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	mainly	PROBABLE_UNDERSTANDING	[22572]	[22578]	PMC3272870.nxml.gz-514
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	may	INCOMPLETE_EVIDENCE	[22584]	[22587]	PMC3272870.nxml.gz-515
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	impact	SUPERFICIAL_RELATIONSHIP	[22628]	[22634]	PMC3272870.nxml.gz-516
PMC3272870	PMC3272870.nxml.gz-510	[22479]	[22667]	Although thyroid cancer during pregnancy may have a faster growth2728since hormonal factors (mainly HCG) may accelerate tumour progression, the real impact of pregnancy seems to be minimal	seems	ANOMALY_CURIOUS_FINDING	[22648]	[22653]	PMC3272870.nxml.gz-517
PMC3272870	PMC3272870.nxml.gz-519	[22669]	[22819]	In fact, the rates of recurrence or the disease-free period do not differ between pregnant and non-pregnant women affected by the same disease22729-32	In fact	ANOMALY_CURIOUS_FINDING	[22669]	[22676]	PMC3272870.nxml.gz-518
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	reported	INCOMPLETE_EVIDENCE	[22832]	[22840]	PMC3272870.nxml.gz-521
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[22902]	[22905]	PMC3272870.nxml.gz-522
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	would	FUTURE_PREDICTION	[22911]	[22916]	PMC3272870.nxml.gz-523
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	appear to be	ANOMALY_CURIOUS_FINDING	[22917]	[22929]	PMC3272870.nxml.gz-524
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	exception	ANOMALY_CURIOUS_FINDING	[22933]	[22942]	PMC3272870.nxml.gz-525
PMC3272870	PMC3272870.nxml.gz-520	[22821]	[22965]	Hod et al. reported a single case of accelerated tumour growth during pregnancy, but this would appear to be an exception rather than the rule29	rather	ALTERNATIVE_OPTIONS_CONTROVERSY	[22943]	[22949]	PMC3272870.nxml.gz-526
PMC3272870	PMC3272870.nxml.gz-527	[22967]	[23177]	In a large retrospective study on 595 pregnancy-associated thyroid cancers, Yasmeen et al. detected no difference in outcome, disease-free survival and morbidity when compared to age-matched non-pregnant women2	associated	SUPERFICIAL_RELATIONSHIP	[23015]	[23025]	PMC3272870.nxml.gz-528
PMC3272870	PMC3272870.nxml.gz-527	[22967]	[23177]	In a large retrospective study on 595 pregnancy-associated thyroid cancers, Yasmeen et al. detected no difference in outcome, disease-free survival and morbidity when compared to age-matched non-pregnant women2	detected	INCOMPLETE_EVIDENCE	[23058]	[23066]	PMC3272870.nxml.gz-529
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	Differently	ALTERNATIVE_OPTIONS_CONTROVERSY	[23179]	[23190]	PMC3272870.nxml.gz-531
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	observed	INCOMPLETE_EVIDENCE	[23204]	[23212]	PMC3272870.nxml.gz-533
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[23216]	[23221]	PMC3272870.nxml.gz-534
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	associated	SUPERFICIAL_RELATIONSHIP	[23232]	[23242]	PMC3272870.nxml.gz-535
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	no	FULL_UNKNOWN	[23252]	[23254]	PMC3272870.nxml.gz-536
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	has been	INCOMPLETE_EVIDENCE	[23295]	[23303]	PMC3272870.nxml.gz-537
PMC3272870	PMC3272870.nxml.gz-530	[23179]	[23312]	Differently from what is observed in other pregnancy-associated cancers, no metastasis of DTC to placenta or foetus has been reported	reported	INCOMPLETE_EVIDENCE	[23304]	[23312]	PMC3272870.nxml.gz-538
PMC3272870	PMC3272870.nxml.gz-539	[23314]	[23462]	An association between thyroid cancer and parity or full-term pregnancy has been assessed in many studies without significant or conclusive results6	association	SUPERFICIAL_RELATIONSHIP	[23317]	[23328]	PMC3272870.nxml.gz-540
PMC3272870	PMC3272870.nxml.gz-539	[23314]	[23462]	An association between thyroid cancer and parity or full-term pregnancy has been assessed in many studies without significant or conclusive results6	has been	INCOMPLETE_EVIDENCE	[23386]	[23394]	PMC3272870.nxml.gz-541
PMC3272870	PMC3272870.nxml.gz-539	[23314]	[23462]	An association between thyroid cancer and parity or full-term pregnancy has been assessed in many studies without significant or conclusive results6	many studies	INCOMPLETE_EVIDENCE	[23407]	[23419]	PMC3272870.nxml.gz-542
PMC3272870	PMC3272870.nxml.gz-539	[23314]	[23462]	An association between thyroid cancer and parity or full-term pregnancy has been assessed in many studies without significant or conclusive results6	without ... conclusive	ALTERNATIVE_OPTIONS_CONTROVERSY	[23420, 23443]	[23427, 23453]	PMC3272870.nxml.gz-545
PMC3272870	PMC3272870.nxml.gz-550	[23564]	[23665]	Pregnancyassociated immune tolerance, designed for foetal survival, might enhance disease progression	associated	SUPERFICIAL_RELATIONSHIP	[23573]	[23583]	PMC3272870.nxml.gz-551
PMC3272870	PMC3272870.nxml.gz-550	[23564]	[23665]	Pregnancyassociated immune tolerance, designed for foetal survival, might enhance disease progression	might	INCOMPLETE_EVIDENCE	[23632]	[23637]	PMC3272870.nxml.gz-552
PMC3272870	PMC3272870.nxml.gz-550	[23564]	[23665]	Pregnancyassociated immune tolerance, designed for foetal survival, might enhance disease progression	enhance	INCOMPLETE_EVIDENCE	[23638]	[23645]	PMC3272870.nxml.gz-553
PMC3272870	PMC3272870.nxml.gz-555	[23667]	[23854]	However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time	However	ALTERNATIVE_OPTIONS_CONTROVERSY	[23667]	[23674]	PMC3272870.nxml.gz-554
PMC3272870	PMC3272870.nxml.gz-555	[23667]	[23854]	However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time	according to	INCOMPLETE_EVIDENCE	[23676]	[23688]	PMC3272870.nxml.gz-556
PMC3272870	PMC3272870.nxml.gz-555	[23667]	[23854]	However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time	literature data	INCOMPLETE_EVIDENCE	[23689]	[23704]	PMC3272870.nxml.gz-557
PMC3272870	PMC3272870.nxml.gz-555	[23667]	[23854]	However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time	our own experience	INCOMPLETE_EVIDENCE	[23709]	[23727]	PMC3272870.nxml.gz-558
PMC3272870	PMC3272870.nxml.gz-555	[23667]	[23854]	However, according to literature data and our own experience pregnancy after thyroid cancer has been shown to have no significant effect on morbidity, disease-free period or survival time	has been shown	INCOMPLETE_EVIDENCE	[23759]	[23773]	PMC3272870.nxml.gz-559
PMC3272870	PMC3272870.nxml.gz-560	[23856]	[23977]	Pregnant women with thyroid cancer have been shown to have favourable outcomes regardless of the timing of diagnosis13233	have been shown	INCOMPLETE_EVIDENCE	[23891]	[23906]	PMC3272870.nxml.gz-561
PMC3272870	PMC3272870.nxml.gz-560	[23856]	[23977]	Pregnant women with thyroid cancer have been shown to have favourable outcomes regardless of the timing of diagnosis13233	regardless of	INCOMPLETE_EVIDENCE	[23935]	[23948]	PMC3272870.nxml.gz-562
PMC3272870	PMC3272870.nxml.gz-563	[23979]	[24101]	Guidelines for evaluation and treatment of thyroid cancer must consider the gestational age but also the patients' desires	Guidelines	PROBABLE_UNDERSTANDING	[23979]	[23989]	PMC3272870.nxml.gz-565
PMC3272870	PMC3272870.nxml.gz-563	[23979]	[24101]	Guidelines for evaluation and treatment of thyroid cancer must consider the gestational age but also the patients' desires	must	IMPORTANT_CONSIDERATION	[24037]	[24041]	PMC3272870.nxml.gz-566
PMC3272870	PMC3272870.nxml.gz-563	[23979]	[24101]	Guidelines for evaluation and treatment of thyroid cancer must consider the gestational age but also the patients' desires	consider	IMPORTANT_CONSIDERATION	[24042]	[24050]	PMC3272870.nxml.gz-568
PMC3272870	PMC3272870.nxml.gz-563	[23979]	[24101]	Guidelines for evaluation and treatment of thyroid cancer must consider the gestational age but also the patients' desires	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[24071]	[24074]	PMC3272870.nxml.gz-569
PMC3272870	PMC3272870.nxml.gz-570	[24103]	[24270]	Detecting a thyroid cancer during pregnancy should not be a reason for termination of pregnancy, and in the large majority of cases it does not require urgent surgery4	should not be	FUTURE_WORK	[24147]	[24160]	PMC3272870.nxml.gz-571
PMC3272870	PMC3272870.nxml.gz-570	[24103]	[24270]	Detecting a thyroid cancer during pregnancy should not be a reason for termination of pregnancy, and in the large majority of cases it does not require urgent surgery4	majority	PROBABLE_UNDERSTANDING	[24217]	[24225]	PMC3272870.nxml.gz-572
PMC3272870	PMC3272870.nxml.gz-570	[24103]	[24270]	Detecting a thyroid cancer during pregnancy should not be a reason for termination of pregnancy, and in the large majority of cases it does not require urgent surgery4	not require	IMPORTANT_CONSIDERATION	[24243]	[24254]	PMC3272870.nxml.gz-30901
PMC3272870	PMC3272870.nxml.gz-574	[24272]	[24358]	The problem of pregnancy-associated thyroid cancer can affect three groups of patients	problem	IMPORTANT_CONSIDERATION	[24276]	[24283]	PMC3272870.nxml.gz-575
PMC3272870	PMC3272870.nxml.gz-574	[24272]	[24358]	The problem of pregnancy-associated thyroid cancer can affect three groups of patients	associated	SUPERFICIAL_RELATIONSHIP	[24297]	[24307]	PMC3272870.nxml.gz-577
PMC3272870	PMC3272870.nxml.gz-574	[24272]	[24358]	The problem of pregnancy-associated thyroid cancer can affect three groups of patients	can	INCOMPLETE_EVIDENCE	[24323]	[24326]	PMC3272870.nxml.gz-578
PMC3272870	PMC3272870.nxml.gz-574	[24272]	[24358]	The problem of pregnancy-associated thyroid cancer can affect three groups of patients	affect	SUPERFICIAL_RELATIONSHIP	[24327]	[24333]	PMC3272870.nxml.gz-579
PMC3272870	PMC3272870.nxml.gz-582	[24496]	[24632]	For these patients, surgery could be safely performed during the mid-trimester or delayed until delivery without worsening prognosis3034	could be	INCOMPLETE_EVIDENCE	[24524]	[24532]	PMC3272870.nxml.gz-583
PMC3272870	PMC3272870.nxml.gz-582	[24496]	[24632]	For these patients, surgery could be safely performed during the mid-trimester or delayed until delivery without worsening prognosis3034	safely	IMPORTANT_CONSIDERATION	[24533]	[24539]	PMC3272870.nxml.gz-584
PMC3272870	PMC3272870.nxml.gz-591	[24793]	[24919]	When surgery is planned during pregnancy, it is important to consider both gestational age and the type of general anaesthesia	important	IMPORTANT_CONSIDERATION	[24841]	[24850]	PMC3272870.nxml.gz-592
PMC3272870	PMC3272870.nxml.gz-591	[24793]	[24919]	When surgery is planned during pregnancy, it is important to consider both gestational age and the type of general anaesthesia	consider	IMPORTANT_CONSIDERATION	[24854]	[24862]	PMC3272870.nxml.gz-594
PMC3272870	PMC3272870.nxml.gz-595	[24921]	[25021]	Whenever possible, the operation should be performed during the second trimester or after delivery37	Whenever	ALTERNATIVE_OPTIONS_CONTROVERSY	[24921]	[24929]	PMC3272870.nxml.gz-596
PMC3272870	PMC3272870.nxml.gz-595	[24921]	[25021]	Whenever possible, the operation should be performed during the second trimester or after delivery37	possible	INCOMPLETE_EVIDENCE	[24930]	[24938]	PMC3272870.nxml.gz-597
PMC3272870	PMC3272870.nxml.gz-595	[24921]	[25021]	Whenever possible, the operation should be performed during the second trimester or after delivery37	should be	IMPORTANT_CONSIDERATION	[24954]	[24963]	PMC3272870.nxml.gz-599
PMC3272870	PMC3272870.nxml.gz-600	[25023]	[25188]	During the first trimester, which is the organogenesis period, general anaesthetic agents may have some teratogenic potential or may increase the risk of miscarriage	may	INCOMPLETE_EVIDENCE	[25113]	[25116]	PMC3272870.nxml.gz-601
PMC3272870	PMC3272870.nxml.gz-600	[25023]	[25188]	During the first trimester, which is the organogenesis period, general anaesthetic agents may have some teratogenic potential or may increase the risk of miscarriage	some	INCOMPLETE_EVIDENCE	[25122]	[25126]	PMC3272870.nxml.gz-602
PMC3272870	PMC3272870.nxml.gz-600	[25023]	[25188]	During the first trimester, which is the organogenesis period, general anaesthetic agents may have some teratogenic potential or may increase the risk of miscarriage	potential	INCOMPLETE_EVIDENCE	[25139]	[25148]	PMC3272870.nxml.gz-603
PMC3272870	PMC3272870.nxml.gz-600	[25023]	[25188]	During the first trimester, which is the organogenesis period, general anaesthetic agents may have some teratogenic potential or may increase the risk of miscarriage	may	INCOMPLETE_EVIDENCE	[25152]	[25155]	PMC3272870.nxml.gz-604
PMC3272870	PMC3272870.nxml.gz-605	[25190]	[25249]	In the third trimester, surgery may induce premature labour	may	INCOMPLETE_EVIDENCE	[25222]	[25225]	PMC3272870.nxml.gz-606
PMC3272870	PMC3272870.nxml.gz-607	[25251]	[25507]	Physiological changes of pregnancy, such as increased heart rate and blood volume, may complicate general anaesthesia, and hypotension caused by vena cava compression of the uterus during a long period in the supine position may cause foetal hypoperfusion1	may	INCOMPLETE_EVIDENCE	[25334]	[25337]	PMC3272870.nxml.gz-608
PMC3272870	PMC3272870.nxml.gz-607	[25251]	[25507]	Physiological changes of pregnancy, such as increased heart rate and blood volume, may complicate general anaesthesia, and hypotension caused by vena cava compression of the uterus during a long period in the supine position may cause foetal hypoperfusion1	may	INCOMPLETE_EVIDENCE	[25476]	[25479]	PMC3272870.nxml.gz-609
PMC3272870	PMC3272870.nxml.gz-610	[25509]	[25747]	Postponing surgery to at least 6-7 months after diagnosis of DTC in the first trimester does not adversely affect prognosis; on the other hand, thyroidectomy can be safely performed in the second trimester of pregnancy or after delivery15	at least	PROBABLE_UNDERSTANDING	[25531]	[25539]	PMC3272870.nxml.gz-611
PMC3272870	PMC3272870.nxml.gz-610	[25509]	[25747]	Postponing surgery to at least 6-7 months after diagnosis of DTC in the first trimester does not adversely affect prognosis; on the other hand, thyroidectomy can be safely performed in the second trimester of pregnancy or after delivery15	on the other hand	ALTERNATIVE_OPTIONS_CONTROVERSY	[25634]	[25651]	PMC3272870.nxml.gz-612
PMC3272870	PMC3272870.nxml.gz-610	[25509]	[25747]	Postponing surgery to at least 6-7 months after diagnosis of DTC in the first trimester does not adversely affect prognosis; on the other hand, thyroidectomy can be safely performed in the second trimester of pregnancy or after delivery15	can	INCOMPLETE_EVIDENCE	[25667]	[25670]	PMC3272870.nxml.gz-613
PMC3272870	PMC3272870.nxml.gz-610	[25509]	[25747]	Postponing surgery to at least 6-7 months after diagnosis of DTC in the first trimester does not adversely affect prognosis; on the other hand, thyroidectomy can be safely performed in the second trimester of pregnancy or after delivery15	safely	IMPORTANT_CONSIDERATION	[25674]	[25680]	PMC3272870.nxml.gz-614
PMC3272870	PMC3272870.nxml.gz-615	[25749]	[25992]	Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring	should be	IMPORTANT_CONSIDERATION	[25766]	[25775]	PMC3272870.nxml.gz-617
PMC3272870	PMC3272870.nxml.gz-615	[25749]	[25992]	Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring	because	PROBLEM_COMPLICATION	[25810]	[25817]	PMC3272870.nxml.gz-618
PMC3272870	PMC3272870.nxml.gz-615	[25749]	[25992]	Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring	may	INCOMPLETE_EVIDENCE	[25843]	[25846]	PMC3272870.nxml.gz-619
PMC3272870	PMC3272870.nxml.gz-615	[25749]	[25992]	Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring	may	INCOMPLETE_EVIDENCE	[25908]	[25911]	PMC3272870.nxml.gz-620
PMC3272870	PMC3272870.nxml.gz-615	[25749]	[25992]	Thyroxin therapy should be started immediately after surgery because untreated hypothyroidism may expose the mother to a higher risk of disease recurrence and may have an adverse effect on cognitive function and regular growth of the offspring	effect	SUPERFICIAL_RELATIONSHIP	[25928]	[25934]	PMC3272870.nxml.gz-621
PMC3272870	PMC3272870.nxml.gz-622	[25994]	[26144]	Regular assessments of TSH and fT4 levels every 6/8 weeks during pregnancy and breast-feeding are required to ensure an adequate dose of levothyroxine	required	IMPORTANT_CONSIDERATION	[26092]	[26100]	PMC3272870.nxml.gz-623
PMC3272870	PMC3272870.nxml.gz-624	[26146]	[26270]	Follow-up may be carried out on a regular basis with ultrasound techniques and thyroglobulin assay, as in non-pregnant women	may be	INCOMPLETE_EVIDENCE	[26156]	[26162]	PMC3272870.nxml.gz-625
PMC3272870	PMC3272870.nxml.gz-624	[26146]	[26270]	Follow-up may be carried out on a regular basis with ultrasound techniques and thyroglobulin assay, as in non-pregnant women	as in	INCOMPLETE_EVIDENCE	[26246]	[26251]	PMC3272870.nxml.gz-626
PMC3272870	PMC3272870.nxml.gz-627	[26272]	[26357]	Radioiodine therapy, when needed, can be safely postponed until after breast- feeding	when needed	ALTERNATIVE_OPTIONS_CONTROVERSY	[26293]	[26304]	PMC3272870.nxml.gz-628
PMC3272870	PMC3272870.nxml.gz-627	[26272]	[26357]	Radioiodine therapy, when needed, can be safely postponed until after breast- feeding	can	INCOMPLETE_EVIDENCE	[26306]	[26309]	PMC3272870.nxml.gz-629
PMC3272870	PMC3272870.nxml.gz-627	[26272]	[26357]	Radioiodine therapy, when needed, can be safely postponed until after breast- feeding	safely	IMPORTANT_CONSIDERATION	[26313]	[26319]	PMC3272870.nxml.gz-630
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	Whether	ALTERNATIVE_OPTIONS_CONTROVERSY	[26533]	[26540]	PMC3272870.nxml.gz-633
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	should	EXPLICIT_QUESTION	[26574]	[26580]	PMC3272870.nxml.gz-635
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	concern	PROBLEM_COMPLICATION	[26618]	[26625]	PMC3272870.nxml.gz-636
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[26627]	[26630]	PMC3272870.nxml.gz-637
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	current evidence	INCOMPLETE_EVIDENCE	[26631]	[26647]	PMC3272870.nxml.gz-638
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	suggests	INCOMPLETE_EVIDENCE	[26648]	[26656]	PMC3272870.nxml.gz-639
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	should	FUTURE_WORK	[26666]	[26672]	PMC3272870.nxml.gz-640
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	recommendation	FUTURE_WORK	[26723]	[26737]	PMC3272870.nxml.gz-641
PMC3272870	PMC3272870.nxml.gz-634	[26533]	[26799]	Whether women treated for thyroid cancer should become pregnant was once a matter of concern, but current evidence suggests that DTC should not discourage intended pregnancy, with the usual recommendation to postpone it to at least 6 months after radioiodine therapy	at least	PROBABLE_UNDERSTANDING	[26756]	[26764]	PMC3272870.nxml.gz-642
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	In spite	ANOMALY_CURIOUS_FINDING	[26801]	[26809]	PMC3272870.nxml.gz-643
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	theoretical	INCOMPLETE_EVIDENCE	[26817]	[26828]	PMC3272870.nxml.gz-645
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	indicate	INCOMPLETE_EVIDENCE	[26914]	[26922]	PMC3272870.nxml.gz-646
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	no evidence	INCOMPLETE_EVIDENCE	[26937]	[26948]	PMC3272870.nxml.gz-647
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	can	INCOMPLETE_EVIDENCE	[26969]	[26972]	PMC3272870.nxml.gz-648
PMC3272870	PMC3272870.nxml.gz-644	[26801]	[26999]	In spite of the theoretical proliferative stimulation caused by HCG and placental growth factors, published data indicate that there is no evidence that thyroid cancer can be influenced by pregnancy	influenced	SUPERFICIAL_RELATIONSHIP	[26976]	[26986]	PMC3272870.nxml.gz-649
PMC3272870	PMC3272870.nxml.gz-650	[27001]	[27074]	In addition, follow-up studies have shown no significant increase in risk	have shown	INCOMPLETE_EVIDENCE	[27032]	[27042]	PMC3272870.nxml.gz-651
PMC3272870	PMC3272870.nxml.gz-653	[27076]	[27368]	Usually, patients are recommended to postpone pregnancy to 6-12 months after radioiodine (I-131) treatment to avoid a potentially higher risk of miscarriage in the first few months after radioiodine therapy and to allow time enough to exclude residual disease requiring further treatment41438	Usually	INCOMPLETE_EVIDENCE	[27076]	[27083]	PMC3272870.nxml.gz-652
PMC3272870	PMC3272870.nxml.gz-653	[27076]	[27368]	Usually, patients are recommended to postpone pregnancy to 6-12 months after radioiodine (I-131) treatment to avoid a potentially higher risk of miscarriage in the first few months after radioiodine therapy and to allow time enough to exclude residual disease requiring further treatment41438	recommended	FUTURE_WORK	[27098]	[27109]	PMC3272870.nxml.gz-654
PMC3272870	PMC3272870.nxml.gz-653	[27076]	[27368]	Usually, patients are recommended to postpone pregnancy to 6-12 months after radioiodine (I-131) treatment to avoid a potentially higher risk of miscarriage in the first few months after radioiodine therapy and to allow time enough to exclude residual disease requiring further treatment41438	potentially	INCOMPLETE_EVIDENCE	[27194]	[27205]	PMC3272870.nxml.gz-655
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	concern	PROBLEM_COMPLICATION	[27414]	[27421]	PMC3272870.nxml.gz-657
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	due to	PROBLEM_COMPLICATION	[27480]	[27486]	PMC3272870.nxml.gz-658
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	known	INCOMPLETE_EVIDENCE	[27491]	[27496]	PMC3272870.nxml.gz-659
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	effect	SUPERFICIAL_RELATIONSHIP	[27507]	[27513]	PMC3272870.nxml.gz-660
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	theoretical	INCOMPLETE_EVIDENCE	[27535]	[27546]	PMC3272870.nxml.gz-661
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	possibility	INCOMPLETE_EVIDENCE	[27547]	[27558]	PMC3272870.nxml.gz-662
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	may	INCOMPLETE_EVIDENCE	[27567]	[27570]	PMC3272870.nxml.gz-663
PMC3272870	PMC3272870.nxml.gz-656	[27370]	[27674]	Miscarriages or premature birth have raised concern about the use of radioactive iodine in a childbearing age due to the known mutagenic effect of radiation and the theoretical possibility that it may affect germ cells, thereby causing genetic damage, congenital abnormalities and malignancy in offspring	affect	SUPERFICIAL_RELATIONSHIP	[27571]	[27577]	PMC3272870.nxml.gz-664
PMC3272870	PMC3272870.nxml.gz-665	[27676]	[27963]	Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers	potential	INCOMPLETE_EVIDENCE	[27736]	[27745]	PMC3272870.nxml.gz-666
PMC3272870	PMC3272870.nxml.gz-665	[27676]	[27963]	Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[27752]	[27755]	PMC3272870.nxml.gz-667
PMC3272870	PMC3272870.nxml.gz-665	[27676]	[27963]	Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers	experimental evidence	INCOMPLETE_EVIDENCE	[27756]	[27777]	PMC3272870.nxml.gz-668
PMC3272870	PMC3272870.nxml.gz-665	[27676]	[27963]	Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers	failed to reveal	INCOMPLETE_EVIDENCE	[27825]	[27841]	PMC3272870.nxml.gz-669
PMC3272870	PMC3272870.nxml.gz-665	[27676]	[27963]	Virtually any person treated with any dosage of I-131 is at potential risk, but experimental evidence in animals and follow-up studies in humans has failed to reveal any statistically significant effects of I-131 on chromosomal abnormalities, congenital malformation or childhood cancers	effects	SUPERFICIAL_RELATIONSHIP	[27872]	[27879]	PMC3272870.nxml.gz-670
PMC3272870	PMC3272870.nxml.gz-674	[28091]	[28238]	Among those children born from I-131 treated women, the authors found only one case of ventricular septal defect and patent ductus arteriosus223940	found	INCOMPLETE_EVIDENCE	[28155]	[28160]	PMC3272870.nxml.gz-675
PMC3272870	PMC3272870.nxml.gz-674	[28091]	[28238]	Among those children born from I-131 treated women, the authors found only one case of ventricular septal defect and patent ductus arteriosus223940	only	INCOMPLETE_EVIDENCE	[28161]	[28165]	PMC3272870.nxml.gz-676
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	possible	INCOMPLETE_EVIDENCE	[28242]	[28250]	PMC3272870.nxml.gz-678
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	reported	INCOMPLETE_EVIDENCE	[28297]	[28305]	PMC3272870.nxml.gz-679
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[28350]	[28353]	PMC3272870.nxml.gz-680
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	remains	INCOMPLETE_EVIDENCE	[28357]	[28364]	PMC3272870.nxml.gz-681
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	uncertain	FULL_UNKNOWN	[28365]	[28374]	PMC3272870.nxml.gz-682
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	whether	ALTERNATIVE_OPTIONS_CONTROVERSY	[28375]	[28382]	PMC3272870.nxml.gz-683
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	can	INCOMPLETE_EVIDENCE	[28392]	[28395]	PMC3272870.nxml.gz-684
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	either ... or	ALTERNATIVE_OPTIONS_CONTROVERSY	[28406, 28488]	[28412, 28490]	PMC3272870.nxml.gz-685
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	often	PROBABLE_UNDERSTANDING	[28458]	[28463]	PMC3272870.nxml.gz-687
PMC3272870	PMC3272870.nxml.gz-677	[28240]	[28563]	A possible increase in the rate of miscarriages has been reported to occur in the early period after therapy, but it remains uncertain whether abortion can be caused either by I-131 itself, by the thyroid autoimmunity often associated with disease or by the hypothyroid-hyperprolactinaemic status accompanying I-131 therapy	associated	SUPERFICIAL_RELATIONSHIP	[28464]	[28474]	PMC3272870.nxml.gz-688
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	consensus	PROBABLE_UNDERSTANDING	[28577]	[28586]	PMC3272870.nxml.gz-690
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	has been	INCOMPLETE_EVIDENCE	[28587]	[28595]	PMC3272870.nxml.gz-691
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	appear to be	ANOMALY_CURIOUS_FINDING	[28697]	[28709]	PMC3272870.nxml.gz-693
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	associated	SUPERFICIAL_RELATIONSHIP	[28710]	[28720]	PMC3272870.nxml.gz-694
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	recommendation	FUTURE_WORK	[28759]	[28773]	PMC3272870.nxml.gz-695
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	even	ANOMALY_CURIOUS_FINDING	[28837]	[28841]	PMC3272870.nxml.gz-696
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	if	ALTERNATIVE_OPTIONS_CONTROVERSY	[28842]	[28844]	PMC3272870.nxml.gz-697
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	no evidence	INCOMPLETE_EVIDENCE	[28854]	[28865]	PMC3272870.nxml.gz-698
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	could	INCOMPLETE_EVIDENCE	[28900]	[28905]	PMC3272870.nxml.gz-699
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	lead to	SUPERFICIAL_RELATIONSHIP	[28906]	[28913]	PMC3272870.nxml.gz-700
PMC3272870	PMC3272870.nxml.gz-689	[28565]	[28943]	At present, consensus has been reached on the fact that radioiodine treatment of DTC does not affect pregnancy outcome and does not appear to be associated with any genetic risk, with the usual recommendation to delay pregnancy for 6-12 months after radioiodine exposure, even if there is no evidence that pregnancy before this period could lead to a less favourable outcome2238	less favourable	IMPORTANT_CONSIDERATION	[28916]	[28931]	PMC3272870.nxml.gz-702
PMC3272870	PMC3272870.nxml.gz-706	[29053]	[29156]	Management of these patients and providing evidencebased advice are obviously extremely difficult tasks	evidencebased	INCOMPLETE_EVIDENCE	[29096]	[29109]	PMC3272870.nxml.gz-707
PMC3272870	PMC3272870.nxml.gz-706	[29053]	[29156]	Management of these patients and providing evidencebased advice are obviously extremely difficult tasks	advice	FUTURE_WORK	[29110]	[29116]	PMC3272870.nxml.gz-708
PMC3272870	PMC3272870.nxml.gz-706	[29053]	[29156]	Management of these patients and providing evidencebased advice are obviously extremely difficult tasks	obviously	ALTERNATIVE_OPTIONS_CONTROVERSY	[29121]	[29130]	PMC3272870.nxml.gz-709
PMC3272870	PMC3272870.nxml.gz-706	[29053]	[29156]	Management of these patients and providing evidencebased advice are obviously extremely difficult tasks	extremely	IMPORTANT_CONSIDERATION	[29131]	[29140]	PMC3272870.nxml.gz-710
PMC3272870	PMC3272870.nxml.gz-706	[29053]	[29156]	Management of these patients and providing evidencebased advice are obviously extremely difficult tasks	difficult tasks	DIFFICULT_TASK	[29141]	[29156]	PMC3272870.nxml.gz-711
PMC3272870	PMC3272870.nxml.gz-712	[29158]	[29364]	Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated	can	INCOMPLETE_EVIDENCE	[29183]	[29186]	PMC3272870.nxml.gz-713
PMC3272870	PMC3272870.nxml.gz-712	[29158]	[29364]	Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated	reassured	PROBABLE_UNDERSTANDING	[29190]	[29199]	PMC3272870.nxml.gz-714
PMC3272870	PMC3272870.nxml.gz-712	[29158]	[29364]	Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated	does not appear	ANOMALY_CURIOUS_FINDING	[29243]	[29258]	PMC3272870.nxml.gz-715
PMC3272870	PMC3272870.nxml.gz-712	[29158]	[29364]	Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated	therefore	PROBABLE_UNDERSTANDING	[29296]	[29305]	PMC3272870.nxml.gz-717
PMC3272870	PMC3272870.nxml.gz-712	[29158]	[29364]	Patients with active DTC can be reassured that, as mentioned above, pregnancy itself does not appear to increase disease progression, and therefore a gap in treatment during pregnancy is not contraindicated	not contraindicated	INCOMPLETE_EVIDENCE	[29345]	[29364]	PMC3272870.nxml.gz-718
PMC3272870	PMC3272870.nxml.gz-722	[29456]	[29687]	For patients with local recurrent disease, ultrasound controls by skilled hands is of outmost importance, both to help surgeons in selecting tissues for excision and to perform local therapy, such as alcoholization of small lesions	outmost importance	IMPORTANT_CONSIDERATION	[29542]	[29560]	PMC3272870.nxml.gz-723
PMC3272870	PMC3272870.nxml.gz-726	[29689]	[29821]	For patients with advanced disease, ultrasound control of tissue growth can help in therapeutic decisions, such as timing of surgery	can	INCOMPLETE_EVIDENCE	[29761]	[29764]	PMC3272870.nxml.gz-727
PMC3272870	PMC3272870.nxml.gz-728	[29823]	[29956]	Whenever possible, surgery should be carried out during the second trimester or after delivery, as for newly diagnosed thyroid cancer	Whenever	ALTERNATIVE_OPTIONS_CONTROVERSY	[29823]	[29831]	PMC3272870.nxml.gz-729
PMC3272870	PMC3272870.nxml.gz-728	[29823]	[29956]	Whenever possible, surgery should be carried out during the second trimester or after delivery, as for newly diagnosed thyroid cancer	possible	INCOMPLETE_EVIDENCE	[29832]	[29840]	PMC3272870.nxml.gz-730
PMC3272870	PMC3272870.nxml.gz-728	[29823]	[29956]	Whenever possible, surgery should be carried out during the second trimester or after delivery, as for newly diagnosed thyroid cancer	should be	FUTURE_WORK	[29850]	[29859]	PMC3272870.nxml.gz-731
PMC3272870	PMC3272870.nxml.gz-735	[30148]	[30331]	This treatment has been widely used for more than 40 years, with the assumption that suppression of endogenous TSH deprives TSH-dependent DTC cells of the most important growth factor	has been	INCOMPLETE_EVIDENCE	[30163]	[30171]	PMC3272870.nxml.gz-736
PMC3272870	PMC3272870.nxml.gz-735	[30148]	[30331]	This treatment has been widely used for more than 40 years, with the assumption that suppression of endogenous TSH deprives TSH-dependent DTC cells of the most important growth factor	assumption	ALTERNATIVE_OPTIONS_CONTROVERSY	[30217]	[30227]	PMC3272870.nxml.gz-737
PMC3272870	PMC3272870.nxml.gz-740	[30333]	[30459]	Therefore, thyroxine therapy aims at suppressing pituitary secretion of TSH, as indicated by serum TSH levels below 0.05 mIU/L	Therefore	PROBABLE_UNDERSTANDING	[30333]	[30342]	PMC3272870.nxml.gz-739
PMC3272870	PMC3272870.nxml.gz-740	[30333]	[30459]	Therefore, thyroxine therapy aims at suppressing pituitary secretion of TSH, as indicated by serum TSH levels below 0.05 mIU/L	aims	IMPORTANT_CONSIDERATION	[30362]	[30366]	PMC3272870.nxml.gz-741
PMC3272870	PMC3272870.nxml.gz-740	[30333]	[30459]	Therefore, thyroxine therapy aims at suppressing pituitary secretion of TSH, as indicated by serum TSH levels below 0.05 mIU/L	as	PROBABLE_UNDERSTANDING	[30410]	[30412]	PMC3272870.nxml.gz-742
PMC3272870	PMC3272870.nxml.gz-740	[30333]	[30459]	Therefore, thyroxine therapy aims at suppressing pituitary secretion of TSH, as indicated by serum TSH levels below 0.05 mIU/L	indicated	INCOMPLETE_EVIDENCE	[30413]	[30422]	PMC3272870.nxml.gz-743
PMC3272870	PMC3272870.nxml.gz-744	[30461]	[30579]	In univariate analyses, thyroxine therapy apparently helps decrease cancer-related death rates among patients with PTC	apparently	ANOMALY_CURIOUS_FINDING	[30503]	[30513]	PMC3272870.nxml.gz-745
PMC3272870	PMC3272870.nxml.gz-744	[30461]	[30579]	In univariate analyses, thyroxine therapy apparently helps decrease cancer-related death rates among patients with PTC	related	SUPERFICIAL_RELATIONSHIP	[30536]	[30543]	PMC3272870.nxml.gz-746
PMC3272870	PMC3272870.nxml.gz-747	[30581]	[30664]	Many series have reported reduced rates of tumour recurrence both in PTC and in FTC	Many series	INCOMPLETE_EVIDENCE	[30581]	[30592]	PMC3272870.nxml.gz-748
PMC3272870	PMC3272870.nxml.gz-747	[30581]	[30664]	Many series have reported reduced rates of tumour recurrence both in PTC and in FTC	have reported	INCOMPLETE_EVIDENCE	[30593]	[30606]	PMC3272870.nxml.gz-749
PMC3272870	PMC3272870.nxml.gz-750	[30666]	[30881]	Doses of L-thyroxine greater than 150/200 μg (at least 2 μg/kg/day) are usually needed to maintain maternal serum-free thyroxin concentrations within the upper third of the reference range and to suppress TSH levels	at least	PROBABLE_UNDERSTANDING	[30712]	[30720]	PMC3272870.nxml.gz-751
PMC3272870	PMC3272870.nxml.gz-750	[30666]	[30881]	Doses of L-thyroxine greater than 150/200 μg (at least 2 μg/kg/day) are usually needed to maintain maternal serum-free thyroxin concentrations within the upper third of the reference range and to suppress TSH levels	usually	INCOMPLETE_EVIDENCE	[30738]	[30745]	PMC3272870.nxml.gz-752
PMC3272870	PMC3272870.nxml.gz-750	[30666]	[30881]	Doses of L-thyroxine greater than 150/200 μg (at least 2 μg/kg/day) are usually needed to maintain maternal serum-free thyroxin concentrations within the upper third of the reference range and to suppress TSH levels	needed	IMPORTANT_CONSIDERATION	[30746]	[30752]	PMC3272870.nxml.gz-754
PMC3272870	PMC3272870.nxml.gz-756	[30883]	[31057]	Usually the dosage needs to be increased as early as during the fifth week of gestation, and fT4 TSH monitoring is recommended every 6 weeks for adequate adjustment of dosage	Usually	INCOMPLETE_EVIDENCE	[30883]	[30890]	PMC3272870.nxml.gz-755
PMC3272870	PMC3272870.nxml.gz-756	[30883]	[31057]	Usually the dosage needs to be increased as early as during the fifth week of gestation, and fT4 TSH monitoring is recommended every 6 weeks for adequate adjustment of dosage	needs	IMPORTANT_CONSIDERATION	[30902]	[30907]	PMC3272870.nxml.gz-757
PMC3272870	PMC3272870.nxml.gz-756	[30883]	[31057]	Usually the dosage needs to be increased as early as during the fifth week of gestation, and fT4 TSH monitoring is recommended every 6 weeks for adequate adjustment of dosage	recommended	FUTURE_WORK	[30998]	[31009]	PMC3272870.nxml.gz-758
PMC3272870	PMC3272870.nxml.gz-759	[31059]	[31191]	After delivery, thyroxine dose can be gradually reduced to pre-pregnancy levels, while TSH levels should be constantly monitored1015	can	INCOMPLETE_EVIDENCE	[31090]	[31093]	PMC3272870.nxml.gz-760
PMC3272870	PMC3272870.nxml.gz-759	[31059]	[31191]	After delivery, thyroxine dose can be gradually reduced to pre-pregnancy levels, while TSH levels should be constantly monitored1015	while	ALTERNATIVE_OPTIONS_CONTROVERSY	[31140]	[31145]	PMC3272870.nxml.gz-761
PMC3272870	PMC3272870.nxml.gz-759	[31059]	[31191]	After delivery, thyroxine dose can be gradually reduced to pre-pregnancy levels, while TSH levels should be constantly monitored1015	should be	IMPORTANT_CONSIDERATION	[31157]	[31166]	PMC3272870.nxml.gz-763
PMC3272870	PMC3272870.nxml.gz-764	[31193]	[31420]	Patients with MTC whose tumours deriving from C cells are not TSH-dependent do not require suppressive therapy, but only thyroxine replacement therapy after surgery, and the dosages are the same as those used for hypothyroidism	not require	IMPORTANT_CONSIDERATION	[31272]	[31283]	PMC3272870.nxml.gz-766
PMC3272870	PMC3272870.nxml.gz-764	[31193]	[31420]	Patients with MTC whose tumours deriving from C cells are not TSH-dependent do not require suppressive therapy, but only thyroxine replacement therapy after surgery, and the dosages are the same as those used for hypothyroidism	but only	ANOMALY_CURIOUS_FINDING	[31305]	[31313]	PMC3272870.nxml.gz-767
PMC3272870	PMC3272870.nxml.gz-768	[31422]	[31681]	Pregnancy status requires much more accuracy in assessing levothyroxine dosage to protect the foetus from maternal hypothyroidism because, as mentioned above, the mother is the only source of thyroid hormones for the embryo in the first trimester of pregnancy	requires	IMPORTANT_CONSIDERATION	[31439]	[31447]	PMC3272870.nxml.gz-769
PMC3272870	PMC3272870.nxml.gz-768	[31422]	[31681]	Pregnancy status requires much more accuracy in assessing levothyroxine dosage to protect the foetus from maternal hypothyroidism because, as mentioned above, the mother is the only source of thyroid hormones for the embryo in the first trimester of pregnancy	much more	FUTURE_WORK	[31448]	[31457]	PMC3272870.nxml.gz-770
PMC3272870	PMC3272870.nxml.gz-768	[31422]	[31681]	Pregnancy status requires much more accuracy in assessing levothyroxine dosage to protect the foetus from maternal hypothyroidism because, as mentioned above, the mother is the only source of thyroid hormones for the embryo in the first trimester of pregnancy	because	PROBLEM_COMPLICATION	[31552]	[31559]	PMC3272870.nxml.gz-771
PMC3272870	PMC3272870.nxml.gz-777	[31775]	[31941]	Approximately 40-80% of the oral dose is absorbed, with peak serum levels measured within 2-4 hour, and the half-life of the administered dose is approximately 1 week	Approximately	INCOMPLETE_EVIDENCE	[31775]	[31788]	PMC3272870.nxml.gz-776
PMC3272870	PMC3272870.nxml.gz-777	[31775]	[31941]	Approximately 40-80% of the oral dose is absorbed, with peak serum levels measured within 2-4 hour, and the half-life of the administered dose is approximately 1 week	approximately	INCOMPLETE_EVIDENCE	[31921]	[31934]	PMC3272870.nxml.gz-778
PMC3272870	PMC3272870.nxml.gz-779	[31943]	[32112]	The extent of absorption is increased in fasting status and decreased if there is inadequate intestinal absorption, often caused by other drugs, such as ferrous sulphate	if	ALTERNATIVE_OPTIONS_CONTROVERSY	[32013]	[32015]	PMC3272870.nxml.gz-780
PMC3272870	PMC3272870.nxml.gz-779	[31943]	[32112]	The extent of absorption is increased in fasting status and decreased if there is inadequate intestinal absorption, often caused by other drugs, such as ferrous sulphate	inadequate	IMPORTANT_CONSIDERATION	[32025]	[32035]	PMC3272870.nxml.gz-30903
PMC3272870	PMC3272870.nxml.gz-779	[31943]	[32112]	The extent of absorption is increased in fasting status and decreased if there is inadequate intestinal absorption, often caused by other drugs, such as ferrous sulphate	often	PROBABLE_UNDERSTANDING	[32059]	[32064]	PMC3272870.nxml.gz-782
PMC3272870	PMC3272870.nxml.gz-779	[31943]	[32112]	The extent of absorption is increased in fasting status and decreased if there is inadequate intestinal absorption, often caused by other drugs, such as ferrous sulphate	other	ALTERNATIVE_OPTIONS_CONTROVERSY	[32075]	[32080]	PMC3272870.nxml.gz-783
PMC3272870	PMC3272870.nxml.gz-785	[32114]	[32215]	Therefore, during pregnancy, thyroxin and ferrous sulphate doses should be spaced by at least 4 hours	Therefore	PROBABLE_UNDERSTANDING	[32114]	[32123]	PMC3272870.nxml.gz-784
PMC3272870	PMC3272870.nxml.gz-785	[32114]	[32215]	Therefore, during pregnancy, thyroxin and ferrous sulphate doses should be spaced by at least 4 hours	should be	FUTURE_WORK	[32179]	[32188]	PMC3272870.nxml.gz-786
PMC3272870	PMC3272870.nxml.gz-785	[32114]	[32215]	Therefore, during pregnancy, thyroxin and ferrous sulphate doses should be spaced by at least 4 hours	at least	PROBABLE_UNDERSTANDING	[32199]	[32207]	PMC3272870.nxml.gz-787
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	limited	INCOMPLETE_EVIDENCE	[32226]	[32233]	PMC3272870.nxml.gz-789
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	but	ALTERNATIVE_OPTIONS_CONTROVERSY	[32234]	[32237]	PMC3272870.nxml.gz-790
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	still	IMPORTANT_CONSIDERATION	[32238]	[32243]	PMC3272870.nxml.gz-791
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	important	IMPORTANT_CONSIDERATION	[32244]	[32253]	PMC3272870.nxml.gz-792
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	while	ALTERNATIVE_OPTIONS_CONTROVERSY	[32305]	[32310]	PMC3272870.nxml.gz-793
PMC3272870	PMC3272870.nxml.gz-788	[32217]	[32628]	There is limited but still important placental transfer of maternal T4 to the foetus18, while placental type III deiodinase catalyzes the conversion of T4 to the more active form reverse-T3, which crosses the placental barrier, and to the less active 3,3'-diiodothyronine (T2), representing a homeostatic mechanism for maintaining T3production in the placenta when maternal serum T4concentrations are modified18	representing	PROBABLE_UNDERSTANDING	[32495]	[32507]	PMC3272870.nxml.gz-794
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	important	IMPORTANT_CONSIDERATION	[32690]	[32699]	PMC3272870.nxml.gz-796
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	because	PROBLEM_COMPLICATION	[32700]	[32707]	PMC3272870.nxml.gz-797
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	because	PROBABLE_UNDERSTANDING	[32700]	[32707]	PMC3272870.nxml.gz-798
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	often	PROBABLE_UNDERSTANDING	[32804]	[32809]	PMC3272870.nxml.gz-799
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	indispensable	IMPORTANT_CONSIDERATION	[32810]	[32823]	PMC3272870.nxml.gz-800
PMC3272870	PMC3272870.nxml.gz-795	[32630]	[32855]	Frequent monitoring and adjustment of L-T4 dosages are very important because of large fluctuations of T4 metabolism during pregnancy; calcium and D vitamin supplementation, often indispensable, must be carefully tailored2324	must be	IMPORTANT_CONSIDERATION	[32825]	[32832]	PMC3272870.nxml.gz-801
PMC3272870	PMC3272870.nxml.gz-30905	[32870]	[32943]	When treating thyroid cancer in pregnancy, 3 factors should be considered	factors	SUPERFICIAL_RELATIONSHIP	[32915]	[32922]	PMC3272870.nxml.gz-803
PMC3272870	PMC3272870.nxml.gz-30905	[32870]	[32943]	When treating thyroid cancer in pregnancy, 3 factors should be considered	should be	FUTURE_WORK	[32923]	[32932]	PMC3272870.nxml.gz-804
PMC3272870	PMC3272870.nxml.gz-30905	[32870]	[32943]	When treating thyroid cancer in pregnancy, 3 factors should be considered	considered	IMPORTANT_CONSIDERATION	[32933]	[32943]	PMC3272870.nxml.gz-806
PMC3272870	PMC3272870.nxml.gz-30907	[32945]	[33025]	The effect of cancer on pregnancy: No metastasis to placenta or foetus – no IUGR	effect	SUPERFICIAL_RELATIONSHIP	[32949]	[32955]	PMC3272870.nxml.gz-807
PMC3272870	PMC3272870.nxml.gz-808	[33027]	[33086]	Pregnancy does not seem to be compromised by thyroid cancer	seem to be	ANOMALY_CURIOUS_FINDING	[33046]	[33056]	PMC3272870.nxml.gz-809
PMC3272870	PMC3272870.nxml.gz-811	[33088]	[33179]	The effect of pregnancy on cancer: In vitro accelerated cell growth, no effect seen in vivo	effect	SUPERFICIAL_RELATIONSHIP	[33092]	[33098]	PMC3272870.nxml.gz-812
PMC3272870	PMC3272870.nxml.gz-814	[33263]	[33348]	The effects of management modalities on pregnancy outcome: No I-131, tailored therapy	effects	SUPERFICIAL_RELATIONSHIP	[33267]	[33274]	PMC3272870.nxml.gz-815
PMC3272870	PMC3272870.nxml.gz-817	[33350]	[33454]	Critical monthly adjustment of levothyroxine therapy: maintain fT4 in the upper third of reference range	Critical	IMPORTANT_CONSIDERATION	[33350]	[33358]	PMC3272870.nxml.gz-816
